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ABSTRACT  
   
Cardiovascular disease is the leading cause of death in the world, responsible for 
17.3 million deaths annually. Aerobic activity and almond ingestion have a cardio-
protective effect against cardiovascular disease, however, the synergistic effect of both 
interventions is not known. This 8-week randomized, parallel, two-arm study examined 
the combined effect of daily almond ingestion (2.5 ounces) and brisk walking (10,000 
steps per day) compared to ingestion of an isocaloric placebo (4 Tbsp cookie butter) and 
brisk walking (10,000 steps per day) in sedentary adults on various markers of 
cardiovascular health. The additive effect of the daily walking intervention with almond 
consumption resulted in significant differences in total cholesterol with a -11.0 ± 10.5 
and +3.3 ± 15.8 mg/dL (p=0.043) change in the ALM and CON group respectively and 
LDL with a -11.5 ± 7.5 and +0.5 ± 13.7 mg/dL (p=0.025) change in the ALM and CON 
group respectively. There was a trend for TBARS to decrease in the ALM group versus 
the CON group (-0.2 ± 0.8 and +0.3 ± 0.6 nmol MDA/mL (p=0.099) respectively) with a 
large effect size of 0.304 but this did not reach statistical significance. There were no 
significant differences seen in markers of other plasma lipid profile measures, plasma 
inflammatory cytokines, or blood pressure regulation. Results suggest that the simple, 
cost-effective, and accessible intervention of daily brisk walking and almond 
consumption is an effective strategy to reduce cardiovascular disease risk in sedentary 
adults through improvements in cholesterol. This represents a pilot study due to the small 
sample size, therefore, additional studies are needed to determine the impact and 
mechanisms of this synergistic effect. 
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CHAPTER 1 
INTRODUCTION 
Overview 
Cardiovascular disease (CVD) continues to remain the leading cause of death 
worldwide and within the United States.1,2 Globally at present day, CVD accounts for 
17.3 million deaths annually and this amount is anticipated to rise to greater than 23.6 
million by 2030.1 From 2010 to 2030 in the United States alone, total direct healthcare 
costs are estimated to triple and real indirect costs are projected to increase by 61 percent. 
Between the astronomical mortality rates and healthcare costs, it is apparent that this 
represents a significant public health issue. Effective prevention strategies are necessary 
to curb the mounting burden of CVD.3  
Lifestyle modifications including physical activity and a cardio-protective diet 
represent the foundation for CVD prevention and treatment for all individuals even those 
on drug therapy.4 Substantial evidence from epidemiological studies show an inverse 
relationship between physical activity and CVD risk with greater sedentary time 
associated with a 147% and 90% increase risk in CVD and cardiovascular mortality 
respectively.5-9 Literature reveals even simply walking has a negative and dose-dependent 
association with CVD and all-cause mortality with increased distance, duration, pace, and 
energy expenditure.10 The protective effect of aerobic activity against CVD stems from 
exercise enhancing vasodilation via heightened bioavailability of nitric oxide (NO).11 Of 
various cardio-protective dietary factors, nuts have gained significant attention because 
they are rich in unsaturated fatty acids, vegetable proteins, minerals, vitamins, 
antioxidants, dietary fiber, and phytochemicals.12 Large epidemiological studies have 
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consistently illustrated a causal association between nut ingestion and CVD rates and 
mortality across age, sex, various localities, and professions.13-16 Furthermore, 
randomized control trials have shown that nuts have beneficial effects on numerous 
mediators of CVD including blood pressure, lipid profiles, various inflammatory, 
oxidative stress, and endothelial biomarkers.17-21 Almonds in particular have been shown 
to dose-dependently reduce total cholesterol and low-density lipoprotein cholesterol 
(LDL) and lower cardiometabolic risk factors such as inflammatory markers, insulin 
resistance and secretion, and fasting and postprandial glucose insulin resistance.22-31 The 
cardio-protective effect of almonds is attributable to their unique nutrient composition 
containing high levels of L-arginine, a precursor for NO which plays a chief role in 
endothelial function and CVD risk.32-33 
To my knowledge, of the studies that have examined physical activity and almond 
consumption in relation to cardiovascular health, none have investigated the combined 
effects of each intervention on endothelium-dependent vasodilation in otherwise healthy 
sedentary adults. Due to the colossal mortality rates and healthcare costs from CVD and 
the lack of research combining exercise and diet interventions, the question of whether 
daily brisk walking coupled with almond consumption has an additive effect in reducing 
CVD risk therefore is greatly necessitated. If such a simple cost-effective diet and 
accessible exercise strategy is shown effective, the manageable incorporation of almonds 
into the daily diet may benefit a substantial portion of the population, which would 
otherwise be at increased risk of CVD. 
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Purpose of Study 
The objective of this randomized parallel two-arm study was to examine the 
combined effects of daily almond ingestion (2.5 ounces) and brisk walking (10,000 steps 
per day) compared to ingestion of an isocaloric placebo (4 Tbsp of Speculoos Cookie 
Butter) and brisk walking (10,000 steps per day) for 8 weeks in otherwise healthy 
sedentary adults on various markers of cardiovascular health. It was anticipated that 
improvements would be observed in all cardiovascular health measures (decreases in 
blood pressure, C-reactive protein (CRP), oxidative stress, and lipids as well as increases 
in flow-mediated dilation (FMD) and total NO production).  
 
Research Aim & Hypothesis 
• Primary Aim: 
To examine the change in blood pressure regulation in otherwise healthy 
sedentary adults before and after daily almond consumption while on a walking 
program. 
• Primary hypothesis:  
Daily almond ingestion along with brisk walking will act synergistically to 
improve blood pressure regulation as measured by FMD, total NO production, 
and blood pressure in otherwise healthy sedentary adults in comparison to brisk 
walking alone.  
• Secondary Aim: 
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To examine the change in cardiovascular disease risk in otherwise healthy 
sedentary adults before and after daily almond consumption while on a walking 
program. 
• Secondary hypothesis: 
Daily almond ingestion along with brisk walking will act synergistically to 
decrease CVD risk in otherwise healthy sedentary adults via an improvement in 
plasma lipid profile, plasma inflammatory cytokines, and oxidative stress 
biomarkers in comparison to brisk walking alone. 
 
Definition of Terms 
• Atherosclerosis: a condition where arteries build up with plaque resulting in the 
hardening and narrowing of arteries that in turn limits blood flow34  
• Vasodilation: the widening of blood vessels 
• NO: a soluble gas made from L-arginine in endothelial cells that aids in 
maintaining vascular equilibrium including dilator tone35 
• L-arginine: an amino acid which is a precursor for NO so therefore is necessary 
in the conservation of proper arterial function36 
• FMD: non-invasive technique assessing endothelial function via the dilation of 
the brachial artery in response to shear stress37  
• Cytokines: proteins secreted by cells in the immune system that interact with 
other cells38 
• Oxidative stress: an imbalance between reactive oxygen species creation and the 
ability for antioxidants to scavenge free radicals39  
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• Nuts: refer to the nine common tree nuts (i.e. almonds, Brazil nuts, cashews, 
hazel nuts, macadamias, pecans, pine nuts, pistachios, and walnuts) plus peanuts40  
• Phytochemicals: naturally occurring bioactive compounds that play a protective 
role against chronic diseases41  
• Brisk Walking: 40-60% of maximum capacity comparable to a 15 to 20-minute 
mile42  
 
Limitations & Delimitations  
Limitations: 
Limitations of this study include use of a 3-day food record at the beginning and 
end of the study to assess estimated energy intakes, incomplete records of participant 
compliance with the daily study food ingestion (see Appendix A), uncertain compliance 
with walking intensity, a small pilot study sample size of 12 participants, a total study 
duration of 8 weeks which is a relatively short interval to influence some biomarkers of 
CVD risk, and inability to measure the effects of almonds on all inflammatory, oxidative, 
and endothelial biomarkers. There is also a potential for selection bias as the population 
for this study was self-selected. Additionally, antiseptic mouthwash was not controlled 
for and while participants met the inclusion criteria for being sedentary (sit > 8 hours a 
day), many were still physically active. 
 
Delimitations: 
Participants were restricted to only otherwise healthy sedentary (sit > 8 hours a 
day) men and postmenopausal women, aged 20-69 years of age. Therefore, 
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generalizability of study results is limited to individuals who similarly meet the 
aforementioned criteria and cannot be generalized to pre-menopausal women and non-
sedentary individuals. Only women who were post-menopausal were included due to 
heightened CVD risk and to minimize confounding effects of physiological hormonal 
fluctuations.43,44  
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CHAPTER 2 
REVIEW OF LITERATURE 
Cardiovascular Disease 
 
Definition 
CVD refers to several heart and blood vessel conditions including coronary heart 
disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, 
congenital heart disease, deep vein thrombosis and pulmonary embolism.45 Table 1 
further describes the various CVD disorders.  
Table 1. CVD Disorders  
Types of CVD Definition 
Coronary Heart Disease Disorder of blood vessels supplying the heart 
Cerebrovascular Disease Disorder of blood vessels supplying the brain 
Peripheral Arterial Disease Disorder of blood vessels supplying the extremities 
Rheumatic Heart Disease Cardiac muscle and value damage due to rheumatic fever 
Congenital Heart Disease Heart structure abnormalities from birth 
Deep Vein Thrombosis & 
Pulmonary Embolism 
Blood clots in veins of the legs (upon dislodgement can travel to 
lungs and heart) 
 
Mortality & Costs 
CVD is the leading cause of death in the world, responsible for 17.3 million 
deaths annually, as well as in the United States, accounting for approximately 1 in every 
3 deaths or 787,000 deaths in 2011.1 Along with mortality, CVD can inflict long-term 
disability on individuals due to complications of strokes, heart attacks, and heart failure.46 
Therefore, overall costs related to CVD are astronomical at an estimated $320.1 billion in 
the United States in 2011.47 From this, $195.6 billion are related to direct costs such as 
physicians, healthcare services, and medication and $124.5 billion are related to indirect 
costs such as lost future productivity from premature mortality.47 This constitutes 15% of 
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total health expenditures in 2011 which is more than any other major diagnostic group.47 
The projections are not promising as the American Heart Association anticipates that by 
2030, 43.9% of the United States population will suffer from CVD with direct costs 
expected to increase to $918 billion and indirect costs expected to increase to $290 
billion.47 However, due to the numerous modifiable risk factors, over 200,000 annual 
deaths from heart disease and stroke are considered preventable in the United States.48  
 
Risk Factors 
Non-modifiable risk factors for CVD include age, sex, race, and family history.49 
Risk increases with age with approximately 80% of deaths due to CVD occurring in 
individuals ≥ 65 years of age.50 For women, age becomes a risk factor at 55 years due to 
the fact that after menopause CVD risk increases because of a decrease in estrogen 
production.51 Men have a greater risk of CVD than pre-menopausal women, however, 
once menopause has occurred, a woman’s risk is similar to a man’s.49 Individuals with 
Asian or African ethnic descent, have increased risk for CVD than other racial groups.49  
This may be due to the fact that African American adults have among the greatest 
prevalence of hypertension globally and South Asians have a greater prevalence of 
diabetes compared to other populations.47,52 Risk also increases if a first-degree blood 
relative has had a stroke or coronary heart disease before age 55, for a male relative, or 
age 65, for a female relative.49 
Modifiable risk factors include hypertension, hypercholesterolemia, tobacco use 
(smoking or chewing), diabetes, obesity, excessive alcohol consumption, poor diet, 
physical inactivity, among others.49 Hypertension represents the greatest risk factor for 
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stroke.49 Living with diabetes makes one twice as likely to develop CVD than a non-
diabetic, a high saturated fat diet is approximated to cause roughly 11% of stroke and 
31% of coronary heart disease globally, and physical inactivity raises heart disease and 
stroke risk by 50%.49 Other modifiable risk factors that increase CVD risk include low 
socio-economic status, chronic stress, anxiety and depression, social isolation, and 
specific treatments such as contraceptive pills and hormone replacement therapy.49 
 
Pathophysiology 
 
Atherosclerosis 
 
Cardiovascular risk factors mentioned above increase the risk for atherosclerosis 
by damaging the vascular endothelium. Atherosclerosis, a condition of chronic 
inflammation of arteries, represents the chief cause of CVD.53 The process of 
atherosclerosis includes 4 major sequential events that play a role in CVD: activation of 
the endothelium and inflammation; accumulation, retention, and alteration of lipoproteins 
and emergence of foam cells; development of complex plaques, augmentation of the 
necrotic core, fibrosis, thrombosis, and remodeling; and inducement of life-threatening 
events.54  
Activation of the atherosclerotic process largely occurs when cardiovascular risk 
factors (i.e. hypertension, hypercholesterolemia, smoking, and diabetes) initiate and/or 
injure the endothelial cells lining blood vessels through mechanical, chemical, or 
immunological insult.55 An inflammatory response cascade is then set in motion.55 
Endothelial cells start to produce cell surface adhesion molecules including but not 
limited to vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant 
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protein-1 (MCP-1) which attract monocytes, T-lymphocytes, neutrophils, and various 
other immune cells to attach to the endothelium and migrate into the sub-endothelial 
space where monocytes differentiate into macrophages.53,54 As tight junctions become 
loose, lipoproteins, especially  LDL, also move into the arterial wall where exposure to 
macrophage, endothelial, and smooth muscle cell oxidants cause oxidation.53,56 Vascular 
smooth muscle cells (VSMC) and macrophages take up increasing amounts of oxidized 
lipoproteins which are then referred to as foam cells.54 As VSMC, lipids, and other 
migrating cells accumulate in the sub-endothelial space an expanding lesion is created 
known as an atherosclerotic plaque that obtrudes the arterial lumen.54 As the plaque 
increases in size, a fibrous cap is formed to cover it that acts as a protective barrier 
between prothrombotic plaque matter and platelets.53,57 Apoptosis combined with 
phagocytic removal can curb plaque growth in inceptive lesions, however, this equal 
coupling does not occur in advanced lesions.58 Buildup of necrotic cells stimulates the 
release of additional inflammatory cytokines such as IFN- causing inhibition of VSMC 
collagen development and matrix-dissolving enzymes such as matrix metalloproteases 
(MMPs) causing break down of collagen fibrils.54,59 This leads to increased fragility of 
the plaque and fibrous cap and therefore greater susceptibility to plaque rupture.54,59 
Plaque rupture can result in thrombosis via the introduction of blood to tissue factors 
initiating coagulation and mobilizing platelets and subsequent tissue infarction thus 
ensuing CVD.54,59  
 
Impaired NO Bioavailability 
A central contributing factor to CVD is the impairment of NO bioavailability. 
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Many of the CVD risk factors mentioned above simulate processes that ultimately lead to 
this distinct manifestation of endothelial dysfunction.60,61 Various factors contribute to 
reduced NO bioavailability including endothelial NO synthase (eNOS) uncoupling, 
oxidative stress, decreased eNOS activity and expression, arginase upregulation, and 
eNOS inhibitors such as asymmetric dimethylarginine (ADMA).60-63  
NO is generated in numerous different cell types by NO synthase (NOS).60 The 
three isoforms of NOS include neuronal (nNOS), endothelial (eNOS), and inducible 
(iNOS) all of which use a number of cofactors along with L-arginine and oxygen in an 
electron transfer reaction to produce NO and L-citrulline.60,64 For example, in a healthy 
blood vessel in response to shear stress and other stimuli, eNOS and cofactors such as 
reduced tetrahydrobiopterin (BH4) are activated causing the generation of NO and L-
citrulline from L-arginine.60 Then NO diffuses to the smooth muscle cells, binds to the 
reduced haem (Fe2+) of soluble guanylyl cyclase (sGC) producing cyclic guanosine 
monophosphate (cGMP) which gives rise to vasodilation.60 In an example of endothelial 
dysfunction, BH4 becomes oxidized to dihyrobiopterin (BH2) causing eNOS 
uncoupling.60 NADPH electrons uncouple from L-arginine oxidation producing 
superoxide (O2•-)  instead of NO.60,65,66 States of inflammation and oxidative stress 
activate oxidase enzymes which can react with NO to create peroxynitrite (ONOO-) 
additionally curbing NO bioavailability.60,66 Furthermore, the reactive oxygen and 
nitrogen species can oxide the haem in sGC desensitizing it to NO activation.60 
Inflammation also leads to upregulation of arginase which shares the same L-arginine 
substrate as NOS.60 Therefore, substrate competition decreases L-arginine levels required 
for de novo NO synthesis and engenders a reduction in NOS activity.60  
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Decreased NO bioavailability can play a part in all stages of atherosclerosis 
progression.61 In the beginning of this disease process, diminished NO can make the 
endothelium susceptible to heightened leukocyte diapedesis, increasing the likelihood of 
LDL oxidation in the sub-endothelium, allowing for uncurbed neointimal hyperplasia.61 
In the later stages, exacerbated platelet activation from reduced NO can result in 
thrombosis and stroke.61 NO is a vital regulator of the vasculature and reduced 
bioavailability is involved in atherosclerotic vascular disease initiation, advancement, and 
future cardiovascular events.67 
Biomarkers of CVD 
A biomarker is regarded as a measurement of a pathological, physiological, or 
therapeutic response.68,69 Cardiology biomarker investigation has mainly focused on 
circulating and imaging markers.68 A plethora of biomarkers have been identified in 
relation to CVD but only the biomarkers pertaining to the pilot study will be addressed 
here as it is out of the scope of this thesis to include all established markers.  
Circulating 
LDL: Lipids are associated with a sound predictive potential for initial CVD events.70 
There is a well-established relationship between plasma LDL and total cholesterol and 
CVD risk as LDL cholesterol has a crucial role in the emergence and clinical indication 
of atherosclerosis.71,72  Multiple clinical trials illustrate LDL reduction produces a dose-
dependent decrease in CVD events.68 Current CVD risk assessments and guidelines 
include LDL and/or total cholesterol as the foundation.68,73 With the well-founded 
evidence and current practices, LDL, therefore, is an essential aspect of CVD risk 
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assessments in addition to pharmacological therapy targets.68  
 
High-density lipoprotein (HDL): HDL is a lipoprotein that carries LDL cholesterol 
from the arteries back to the liver which breaks it down and then it is excreted from the 
body.74 Substantial evidence illustrates the inverse and independent association of low 
HDL concentrations with increased CVD risk.72,75,76 This is due to many cardioprotective 
mechanisms of HDL including endothelial dysfunction improvement, activation of 
macrophage cholesterol efflux, and anti-inflammatory, anti-apoptotic, and antioxidant 
properties.77 Macrophage cholesterol efflux where excess cholesterol is removed from 
macrophages and returned to the liver as part of reverse liver transport is the most 
established property related to the cardioprotective effect of HDL.77 As such a strong risk 
factor, HDL is routinely used in CVD risk estimations.76,78  
 
Triglycerides: There is a long-established relationship between high triglyceride levels 
and CVD risk.79 Triglycerides play a vital part in lipid metabolism. Although they are not 
directly atherogenic, they have a recognized association with atherogenic remnants and 
apolipoprotein C-III thus making them a valuable biomarker of CVD.79 
 
CRP: CRP is an acute phase reactant and marker of inflammation mainly produced by 
the liver but also generated by vascular smooth muscle cells.69,80 It represents one of the 
most well-studied inflammatory markers with a strong association to CVD. A wealth of 
evidence exists substantiating the high-sensitivity CRP (hsCRP) assay in CVD event 
prediction as an independent risk marker.80,81 A graded and dose-dependent relationship 
has been demonstrated with controlling for other risk factors in many prospective and 
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nested case control experiments.81  
 
Malondialdehyde (MDA): MDA represents a lipid peroxidation end product that is 
commonly measured as thiobarbituric acid (TBA) reactive substances (TBARS), which is 
an indicator of oxidative stress in CVD models.82,83 Human and animal trials have linked 
oxidative stress via the TBARS assay to CVD risk, progression, and therapy response 
prediction.82-85  
 
NO: Total amounts of nitrate plus nitrite known as the NOx test are commonly used in 
both animal and human studies.86 Nitrite has been shown to be an indicator of CVD risk 
with decreased nitrite amounts associated with increased CVD risk.87 This is largely due 
to the role NO plays as a vasodilator, regulating tone and structure of vasculature, and an 
antioxidant in lipid oxidation.87-89 NO also curbs adhesion and aggregation of leukocytes 
and platelets, inhibits proliferation and migration of VSMCs, regulates microthrombi 
formation and vascular permeability, and exerts anti-inflammatory properties.87,89 
Because of this, reduced NO bioavailability promotes conditions related to CVD 
including hypertension and atherosclerosis.89  
 
Imaging 
FMD: FMD has been shown in numerous studies to be a strong predictor of CVD events 
in subjects with CVD, subjects with a high CVD risk, and in asymptomatic individuals.90 
FMD represents a direct evaluation of arterial function and therefore supplies important 
independent prognostic CVD data.90  
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Dietary Prevention 
Dietary patterns 
There have been several cardioprotective diets identified including vegetarian and 
Japanese diet patterns.12 The dietary patterns that have been more thoroughly 
investigated, however, are the low-fat diet, the low-carbohydrate diet, the Mediterranean 
diet, and the Dietary Approach to Stop Hypertension (DASH) diet.12,91  
A common clinical standard for CVD prevention is a consumption of a diet 
reduced in fat.91 A low-fat diet is defined as total fat ingestion of 25-35% of total calories 
with a maximum for saturated and trans fat being 7-10% and less than 1% respectively.91 
It has been shown to significantly reduce CVD risk and may improve life span and 
quality.91,92  
A low-carbohydrate diet is defined as 30-130 grams of carbohydrates daily.91 In a 
recent systematic review and meta-analysis, a low-carbohydrate diet was demonstrated to 
have advantageous outcomes on key CVD risk factors with significant decreases in 
systolic and diastolic blood pressure, body weight, body mass index (BMI), triglycerides 
and a significant increase in HDL cholesterol.91 A Mediterranean diet is distinguished by 
foods rich in fish and plant-based omega-3 fatty acids.91 This dietary pattern has been 
linked with a low coronary heart disease risk in numerous studies and has been shown to 
lessen CVD event occurrence and is superior to a low-fat diet in decreasing triglycerides, 
increasing HDL, and enhancing insulin sensitivity.91-93  The DASH diet emphasizes 
vegetables, fruits, whole grains, low-fat dairy, and lean protein sources while limiting 
saturated fat, sweets, and fatty meats.91 It has been shown to lower systolic and diastolic 
blood pressure and therefore is recommended to prevent hypertension, a major CVD risk 
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factor.91 
 
Individual food items 
Specific foods in relation to CVD have been studied. For example, whole grain 
consumption lowers total and LDL cholesterol and fiber intake reduces LDL as 
well.91,94,95  Fruit and vegetable consumption is associated with coronary heart disease 
risk reduction and lower blood pressure.91,93,96-101 Other foods that have shown beneficial 
effects on CVD risk include nuts, low-fat milk and dairy products, green tea, chocolate, 
garlic, and red wine.91,102,103 Because this work focuses on nuts, this particular food item 
will solely be expanded on in relation to CVD.  
Nuts are nutrient dense foods because they are rich in protein, fiber, vitamins such 
as niacin, vitamin B-6, folic acid, and tocopherols, minerals such as potassium, calcium, 
and magnesium, phenolic compounds, phytosterols, and L-arginine.91,104 Nuts have a 
distinct fatty acid profile being low in saturated fats (4-16%) and high in 
monounsaturated fats with a moderate amount of polyunsaturated fats such as omega-
3.104 This unique composition of fatty acids and nutrients account for many of their 
reported health benefits.104 
Epidemiological studies have consistently demonstrated an inverse association 
between nut ingestion and fatal coronary heart disease (CHD) in men and women.105,106 
The major prospective studies include the Adventist Health Study, the Iowa Women’s 
Study, the Nurses’ Health Study, and the Physicians’ Health Study which together show a 
37% average lower risk of CHD death.106 Each of these studies demonstrated a dose-
dependent association between nut consumption and decreased risk of CHD.106 The 
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Adventist Health Study additionally illustrated a significant decrease in nonfatal stroke 
risk whereas the Nurses’ Health Study and Physicians’ Health Study did not.15 Nut intake 
has been shown by meta-analyses not only to be inversely associated with CHD 
incidence but also with all-cause mortality and CVD mortality.18,107 One serving of nuts 
daily reduces all-cause mortality risk by 27% and a daily nut intake of 10 grams or more 
reduces CVD mortality by 17% compared to non-nut consumers.104,108,109 Prospective 
studies have furthermore shown increased nut consumption decreases hypertension risk 
by 13%, 15%, and 18%.105 Increased nut and seed consumption also has an inverse 
association with inflammatory markers such as CRP, fibrinogen, and interleukin-6.19 
Randomized control trials exploring nut-enhanced diets versus control diets for 3 
to 8 week durations clearly displayed nut ingestion ameliorates lipid levels in a dose-
dependent fashion, especially among individuals with elevated LDL, lower BMI, or who 
adhere to a Western diet.18 A pooled examination of 25 intervention studies with an 
average daily nut consumption of 67 grams showed mean total cholesterol reduction of 
10.9 mg/dL (5.1% change), mean LDL reduction of 10.2 mg/dL (7.4% change), mean 
LDL to HDL ratio reduction of 0.22 (8.3% change), mean total cholesterol to HDL ratio 
reduction of 0.24 (5.6% change), and mean triglyceride reduction of 20.6 mg/dL in 
participants with triglycerides of 150 mg/dL or more.91,18 
 
Nutritional supplements 
 Numerous supplements have been studied in regards to CVD but conclusive 
evidence has yet to be shown for the majority of them. Investigated supplements include 
the following: omega-3 and fish oil, phytosterols, antioxidants, vitamin D, magnesium, 
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homocysteine-reducing agents, Coenzyme Q10, and L-arginine.91 
Almonds 
 
Nutrient Composition 
Almonds are a nutrient-rich food and an excellent source of manganese and 
vitamin E (i.e. containing > 20% of the US Daily Value), a good source of magnesium, 
riboflavin, copper, phosphorus, fiber, and protein (i.e. containing 10-20% of the US Daily 
Value) as well as being uniquely high in arginine.110,111 In fact, almonds are deemed one 
of the richest alpha-tocopherol food sources.112 Compared to other nuts, almonds have the 
highest amount of protein, fiber, riboflavin, niacin, vitamin E, and calcium.112 Almonds 
have a high total lipid content ranging from 49-66% of weight within California-grown 
almonds and an unique fatty acid profile of approximately 13 grams of monounsaturated 
fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), 1 gram of saturated fatty 
acids, and no cholesterol per one ounce serving.110,111,113,114 The five predominant fatty 
acids in almonds are as follows in decreasing order: oleic acid (18:1), linoleic acid (18:2), 
palmitic (16:0), stearic (18:0), and palmitoleic (16:1) with the MUFA, oleic acid, making 
up 62-80% of total fatty acids.113-115 Table 2 further delineates the nutrient composition 
and constitutes the most comprehensive cross-sectional data of almonds produced in 
California (see Appendix B for a full nutrient report).  
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Table 2. Nutrient Composition of Almonds Versus Cookie Butter 
Nutrient Unit Almonds (2.5 oz)a,b Cookie Butter (4 Tbsp)a,c 
Macronutrients    
    Water g 3.13 - 
    Energy kcal 410 360 
    Protein g 14.99 4 
    Total fat g 35.39 24 
    Carbohydrate g 15.27 36 
    Dietary fiber g 8.9 0 
    Total sugar g 3.08 20 
Minerals    
    Calcium mg 191 0 
    Iron mg 2.63 0 
    Magnesium mg 191 - 
    Phosphorous mg 341 - 
    Potassium mg 520 - 
    Sodium mg 1 100 
    Zinc mg 2.21 - 
    Copper mg 0.73 - 
    Manganese mg 1.545 - 
    Selenium g 3 - 
Vitamins    
    Thiamin mg 0.145 - 
    Riboflavin mg 0.807 - 
    Niacin mg 2.564 - 
    Pantothenic 
acid 
mg 0.335 - 
    Vitamin B6 mg 0.097 - 
    Total folate g 30 - 
    Vitamin A IU 2.5 0 
    Vitamin E    
Total mg 18.85 4 
        -
Tocopherol 
mg 18.175 - 
        -
Tocopherol 
mg 0.175 - 
        -
Tocopherol 
mg 0.45 - 
        -
Tocopherol 
mg 0.05 - 
Lipids    
    Saturated fats g 2.695 4 
    
Monounsaturated 
fats 
g 22.3625 -  
        18:1 g 22.18 - 
    
Polyunsaturated 
fats 
g 8.738 - 
        18:2 g 8.735 - 
    Phytosterols mg 97.5 - 
Amino acids    
    Lysine g 0.4025 - 
    Arginine g 1.7475 - 
Other    
    Total 
flavonoids 
   
        
Anthocyanidins 
mg 1.75 - 
        Flavan-3-ols mg 3.25 - 
        Flavanones mg 0.5 - 
        Flavonols mg 2.25 - 
        
Proanthocyanidin 
mg 108.5 - 
    Total 
phenolics 
mg 296.25 - 
aNutrient data obtained from USDA National Nutrient Database for Standard Reference, Release 28 (2015), slightly revised May 
2016 bNutrient data obtained from Chen et. al., 2006110   cNutrient data obtained from Food Processor Nutrition Analysis Software 
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Almonds additionally possess a variety of phytonutrients consisting of phenolic 
acids, phytosterols, and other polyphenolic compounds like flavonoids and 
proanthocyanidins (see Table 2).110 Phytochemicals are bioactive plant compounds that 
have been shown to have anti-inflammatory, antioxidant, anti-thrombotic, antiviral, anti-
microbial, anti-proliferative, chemopreventative (use of chemical agents either biological, 
synthetic, or natural for reversal, suppression, or inhibition of cancer), vasodilatory, and 
hypocholesterolemic properties.116-119 Therefore, these compounds have been strongly 
associated with risk reductions of various chronic diseases including CVD where there 
has been an inverse association demonstrated with CHD and coronary mortality and an 
inverse correlation shown with total and LDL cholesterol levels and stroke incidence.116 
Thus far, almonds are the only food source found to provide flavanones and almonds, 
along with pistachios, are the only nuts that are known to have flavonols largely as 
isorhamnetin.120  
 As almonds are a natural product, the nutrient composition is anticipated to be 
variable, even within a single cultivar.113 The nutrient make-up for almonds, particularly 
tocopherols, lipids, fatty acids, and phytonutrients, is primarily dependent on genotype as 
well as environment.113 Factors such as geographical region of farming, cultivation 
methods, climate, soil composition, origin of water, irrigation, agronomic aids that differ 
between growing sites, harvest years, and kernel maturity all can influence the nutrient 
content.113 Some phytonutrients are also affected by postharvest processing and storage of 
nuts.117 
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Energy Content 
The United States Department of Agriculture (USDA) currently lists the energy 
value of almonds to be 164 kcal/28 g (1 oz serving).114 This estimate is based on the 
Atwater factors which is a commonly used system to determine the energy content of 
foods.121 However, sizable evidence indicates the Atwater factors may be a poor energy 
predictor for nuts and multiple studies confirm that Atwater factors whether general or 
specific lead to erroneous approximations of the metabolizable energy for almonds.121,122 
This is likely due to the digestibility coefficient, a main piece of the Atwater factors, of 
nuts differing from other foods.121 A recent randomized, crossover controlled feeding 
study found the energy content of almonds to be 4.6  0.8 kcal/g or 129 kcal/28 g 
serving.121 A follow-up study confirmed these results.118 Compared to the current 
Atwater factors applied to almonds of 6.0-6.1 kcal/g or 168-170 kcal/28 g serving, there 
is a large discrepancy present.121 Current research shows that Atwater factors result in a 
32% overestimation for energy content of almonds and, therefore, almonds actually have 
lower energy content than currently listed on Nutrition Facts labels.121 
 
Bioaccessibility of Nutrients 
Bioaccessibility refers to the relative portion of nutrients and phytochemicals 
“released” from a food matrix which are potentially accessible for absorption into the 
gastrointestinal tract.123,124 The proportion of dietary components accessible for 
absorption is dependent on many factors including mastication and physical and chemical 
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food matrix properties (i.e. cell wall composition, structure, and strength, and inter-cell 
adhesion).123,124 
 
Lipids, protein, & alpha-tocopherol 
Lipids are enclosed within almond cell walls therefore making the number of cells 
on the tissue surface ruptured by mastication or mechanical methods the main factor in 
lipid bioaccessibility.123 After mastication, largely only the initial layer of cells at the 
fractured area rupture, allowing the release of lipids.125 Most almond cells stay intact thus 
inhibiting immediate bioaccessibility of intra-cellular lipids and nutrients in the early 
digestion phases.126 This is illustrated by a recent study showing only 8.5% of intra-
cellular lipids are released and that 89-92% of lipids remain within the tissue matrix and a 
second study showing similar results of approximately 10% of intra-cellular lipids being 
released after duodenal digestion.126,127 Limited research has been done on protein and 
alpha-tocopherol bioaccessibility. A 2008 in vitro digestion study found that 
approximately 16.5% and 13.9% of vitamin E and protein were released following 
duodenal digestion, respectively.127 
The documented mechanism of lipid encapsulation leading to severely limited 
bioaccessibility offers a reasonable explanation of the decreased metabolized energy 
content of almonds.126 It also plausibly explains the decreased postprandial lipemic 
response of almonds and the sustained weight loss produced by an almond rich diet, both 
of which have advantageous implications for CVD risk.126  
 
Skin phytochemicals 
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Phytochemicals are an emerging field of research and therefore bioaccessibility 
remains largely unknown.117 The skins of almonds in particular contain large amounts of 
cell wall-bound phenolics as well as fiber.128 The bioaccessibility of almond skin 
polyphenols over the various digestion phases, from the upper GI tract to the duodenum, 
has been demonstrated in multiple stimulated human digestion studies with a few human 
studies further substantiating acute bioavailability.117,128,129 Table 3 delineates the 
amounts of phytochemicals released from almond skins within stimulated human 
digestion.124  
 A variety of factors have been well-documented to affect bioavailability and 
absorption rate of polyphenols including digestion enzymes, gut microbiota interaction, 
food matrix, and chemical structure.128 A 2016 study suggests that the food matrix plays a 
significant role in both gastric and duodenal settings, specifically illustrating that the milk 
matrix significantly decreased phenolic acids and flavan-3-ols released from almond 
skins compared to water and homemade biscuits lowered bioavailability of flavonols.128 
The study also indicates that the innate fiber in almond skins may serve as a barrier for 
phytochemical bioaccessibility during digestion due to the complex carbohydrates within 
fiber directly influencing antioxidants.128 
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Table 3. Almond Skin Phenolic acid and Flavonoid Release During Digestion 
Compound NS G NS G + D 
Protocatechuic acid 34.4 (±5.6) 97.6 (±1.7) 
p-Hydroxybenzoic acid 89.3 (±0.5) 93.3 (±0.5) 
Catechin 89.8 (±0.6) 99.2 (±0.1) 
Chlorogenic acid  85.1 (±0.2) 98.6 (±0.1) 
Vanillic acid 68.7 (±2.4) 88.8 (±0.7) 
Epicatechin 95.7 (±0.2) 97.6 (±0.2) 
trans p-Coumaric acid 73.1 (±1.6) 86.2 (±1.9) 
Eryodictiol-7-O-glucoside 95.3 (±0.3) 97.8 (±0.2) 
Quercetin-3-O-rutinoside 25.1 (±4.7) 68.0 (±1.9) 
Quercetin-3-O-galactoside 59.2 (±5.5) 79.1 (±2.6) 
Quercetin-3-O-glucoside 86.2 (±1.2) 88.6 (±1.2) 
Kaempferol-3-O-rutinoside 91.8 (±0.9) 98.9 (±0.1) 
Naringenin-7-O-glucoside 76.6 (±0.8) 83.8 (±0.9) 
Isorhamnetin-3-O-rutinoside  88.1 (±0.1) 93.2 (±0.2) 
Kaempferol-3-O-glucoside 65.7 (±1.4) 67.4 (±2.2) 
Isorhamnetin-3-O-glucoside 62.7 (±1.3) 66.8 (±1.7) 
Eryodictiol 45.0 (±7.2) 96.3 (±0.5) 
Quercetin 42.4 (±7.7) 53.5 (±4.2) 
Naringenin 61.7 (±3.1) 74.9 (±1.4) 
Kaempferol  28.4 (±4.4) 34.6 (±5.1) 
Isorhamnetin  19.7 (±7.4) 25.1 (±7.0) 
Values expressed as % released from initial amounts present in almond skins during stimulated human digestion. NS = natural skins; 
NS G = natural skins post in vitro gastric digestion; NS G + D = natural skins post in vitro gastric + duodenal digestion. Data obtained 
from Mandalari et. al., 2010123 
 
Protective Role in CVD 
Cholesterol reduction 
The majority of studies conducted in people with hypercholesterolemia illustrate 1 
to 4 ounces of daily almond ingestion results in significant decreases in total and LDL-C 
concentrations.130 A common finding across studies shows a dose response where greater 
almond consumption is associated with larger cholesterol reductions.130 Studies that have 
examined almond consumption in conjunction with a heart healthy diet substantiate the 
cholesterol-lowering effect in hypercholesterolemic individuals.130  
This extensive research on the effects of almond ingestion on lipoprotein profiles 
has been translated into a U.S. Food and Drug administration health claim that almonds 
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can aid in the maintenance of normal cholesterol levels, especially in individuals with 
high cholesterol.111 Appendix C reviews a summary of effects of almonds consumption 
on cholesterol from randomized controlled trials (RCTs) in more detail.  
 
Antioxidation 
As stated, almonds consist of a variety of antioxidants such as alpha-tocopherol 
and numerous phytonutrients.111 Because of the collective action of antioxidants, almonds 
may enhance antioxidant defense capability through the action of scavenging radicals 
and/or up-regulating endogenous antioxidant systems.111  
The majority of clinical trials substantiate that almond nutrients may safeguard 
vulnerable macromolecules against local and systematic oxidation in individuals with 
increased oxidative stress and enhance antioxidant defense.111 Results have shown 
decreased fatty acid peroxidation and postprandial protein oxidative damage and 
increased serum glutathione peroxidase and superoxide dismutase action (see Appendix 
D ).111 It is important to note that such oxidative stress biomarker reductions could reflect 
amelioration of pathological conditions which can cause oxidant production.111 
 
Anti-inflammation 
 The anti-inflammatory action of almonds has been illustrated by numerous studies 
remaining consistent with observational evidence that inflammation biomarkers are 
inversely associated with greater frequency of nut and seed ingestion.111 A good deal of 
empirical evidence shows that almond interventions reduce biomarkers such as CRP, E-
selectin, and interleukin-6.111 The ability of almonds to modulate inflammation, 
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especially in individuals in a heightened inflammatory state are well-supported.111 The 
specific underlying mechanisms of action for such effects calls for more investigation.111 
 
Body weight control 
Contrary to the energy density of almonds, the scientific body of evidence 
indicates almond consumption along with a healthy diet does not increase body weight 
and actually elicits a positive influence on body composition specifically in overweight 
and obese individuals.130 Studies in normal weight individuals have shown daily almond 
ingestion improves satiety and may help to control cravings with no significant 
differences in total daily caloric intake, metabolic rate, or energy expenditure.130  
 
Glucoregulation 
Almonds have demonstrated neutral or favorable influence on postprandial 
plasma glucose and insulin responses in both healthy and hyperlipidemic subjects with 
normal control of blood glucose levels.130 A few studies even illustrated almonds reduced 
glucose and insulin peaks both immediately and 2 hours postprandial compared to a meal 
with no almonds.130 This emerging evidence suggest almonds may aid in lowering the 
risk of CVD as well as metabolic syndrome and Type 2 Diabetes via improved glucose 
regulation.130 
 
Vascular function  
There is currently very limited evidence on the effect of almonds on vascular 
function, in particular to FMD, and the few studies conducted show mixed results. Chen 
et al. demonstrated no advantageous effect on vascular reactivity following a chronic 
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National Cholesterol Education Program (NCEP) Step 1 diet with 85 g of almonds daily 
in patients with compromised endothelial function.46 Choudhury et al. demonstrated 50 g 
of almonds daily enhanced FMD in healthy men compared to no almonds (3.6% vs. 
2.9%).131 Jamshed et al. showed 3 g/kg of almonds daily had a partial effect on vascular 
reactivity.132 The differences in study design and subject characteristics may account for 
the inconsistent results. Table 5 summarizes the effect of almonds on vascular function. 
Table 4. Effect of Almonds on Vascular Function 
Reference Subjects 
Study 
Duration 
Diet Intervention Results 
Chen et al., 
201546 
 
27 F, 18 M, 
CAD 
patients 
22 weeks NCEP Step 1 diet 
absent nuts (CON) vs 
85 g/day into the CON 
diet (ALM) 
Vitamin E: 5.8% ↑ in ALM (p ≤
 0.05)  
FMD, PAT, PWV: no change 
BP, CRP, TNF, E-selectin: no 
significant change 
VCAM-1: 5.3% ↓ trend 
(p=0.064) 
Choudhury 
et al., 
2014131 
 
60 M, 
healthy 
middle-aged 
(20), healthy 
young (20), 
young with 
2+ CV risk 
factors (20) 
4 weeks 50 g almonds/day in 3 
subject groups vs 
habitual diet (control) 
Vitamin E: sig ↑ (p < 0.05) 
Plasma protein oxidation & 
nitrite: no change 
Diastolic BP: 6% ↓ in healthy 
middle-aged, 12% ↓ in healthy 
young, no change in young at risk 
and control  
Systolic BP: 6% ↓ in healthy 
middle-aged, 5% ↓ in healthy 
young, 4% ↓ in young at risk, no 
change in control 
FMD: significant ↑ in young 
groups and trend for ↑ in healthy 
middle-aged  
Jamshed et 
al., 2014132  
14 F/M 
Sprague-
Dawley rats 
4 weeks 3 studies in 3 groups of 
rats:  
1) tyloxapol 
2) a high-fat diet (HFD) 
3) white-flour fructose 
(WFF).  
 
Group 3 in each study 
was fed 3 g/kg 
almonds/day 
Vascular reactivity: partially 
restored isolated aortas, curbed 
HFD-induced endothelial 
dysfunction by decreasing 
inhibition of eNOS and 
encouraging release of NO 
F = female, M = male, CAD = coronary artery disease, CV = cardiovascular, NCEP = National Cholesterol Education Program, FMD 
= flow-mediated dilation, PAT = peripheral arterial tonometry, PWV = pulse wave velocity, BP = blood pressure, CRP = C-reactive 
protein, TNF = tumor necrosis factor, VCAM = vascular cell adhesion molecules, ↓ = decrease, ↑ = increase 
 
  28 
Mechanisms of Action 
Fatty acid profile 
The high unsaturated to saturated fatty acid ratio in almonds promotes a beneficial 
shift in the fatty acid profile of the diet when almond substitution occurs for high 
saturated fat foods.111 A plausible mechanism for this effect is that unsaturated fats 
improve receptor-dependent LDL removal in the liver consequently decreasing LDL 
production.133 Specific unsaturated fatty acid types may have slightly varied effects on 
the lipid profile. MUFA may be favorable to HDL increases while PUFA n-6 may be 
favorable to LDL decreases when isocalorically substituting carbohydrates.133 Table 6 
summarizes the varying lipid profile effects of fatty acids.133 
 
Table 5. Lipid Profile Effect of Fatty Acid Classes 
Fatty acids LDL HDL Triglycerides 
Saturated ↑ ↑ - or ↑ 
Trans ↑ ↓ ↑ 
Cis monounsaturated ↓ - or ↑ ↓ 
Polyunsaturated n-6 ↓ - or ↓ ↓ 
Polyunsaturated n-3 ↑* - ↓ 
↑ increase, ↓ decrease, - no change, *LDL composition altered to larger and less dense particles 
 
 
Arginine content 
Arginine plays a large role in lowering LDL by increasing bile acid output, 
cholesterol turnover, and steroid excretion and decreasing the pool of cholesterol.134 It is 
also possible arginine increases glucagon which lowers cholesterol via a positive effect 
on the insulin to glucagon ratio.134 
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Phytosterol content 
It has been well-documented that phytosterols lower LDL via reduced absorption 
and increased excretion of cholesterol by displacing cholesterol from micelles in the 
intestines and therefore minimizing the supply of absorbable cholesterol.134 Other 
theorized mechanisms for the hypocholesterolemic action includes phytosterol interaction 
with intracellular enzymes allowing for heightened cholesterol transportation from 
plasma cell membranes to the endoplasmic reticulum for chylomicron packaging and 
decreased movement of very low density lipoproteins and chylomicron representative 
apolipoproteins.134   
 
Fiber content 
Viscous fiber in the diet has been clearly illustrated to have cholesterol-lowering 
mechanisms in which it augments excretion of cholesterol and bile acid and upregulates 
LDL receptors through enterohepatic circulation interference.134 The mechanisms of 
insoluble fiber remain less clear. 134 The attributed mechanisms at present for insoluble 
fiber is that of increasing fecal bulk via long-chain polymers binding water and hydrating 
fecal matter and reducing intestinal transit time with an ensuing rise in satiation.134  
 
Protein content 
The partial replacement of carbohydrates with protein has demonstrated 
cardioprotective effects on LDL in healthy and hypercholesterolemic individuals.134 This 
may be attributed to a higher protein and lower carbohydrate diet inhibiting VLDL 
release leading to a decrease in LDL, curbing de novo fatty acid synthesis, and increasing 
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fat oxidation.134 Similarly, with phytosterols, lowered cholesterol levels upregulate LDL 
receptors and thus increase uptake of cholesterol into the liver.134  
 
Alpha-tocopherol content 
It has been well-documented that alpha-tocopherol reduces lipid peroxidation.20 
Mechanisms apart from antioxidants include protein kinase C inhibition leading to 
disruption of monocyte adhesion and multiplication of smooth muscle as well as 
downregulation of lipid homeostatic genes.134 
 
Micronutrient content (Mg, Mn, Cu, Ca, Na:K) 
There is no proven cause and effect relationship with magnesium and CVD due to 
present data mainly being epidemiological and conflicting randomized control trial 
(RCT) results.134 However, an inverse association has been shown between magnesium 
and CAD, high blood pressure, and cardiac arrhythmias which are all cardiovascular risk 
factors.134 There is little evidence on the relationship between manganese and CVD, 
however, there is enough promising results to warrant additional studies.134 Research on 
copper and CVD continues to be controversial although an inverse association between 
copper levels and CVD risk factors, particularly sclerotic development, has been 
demonstrated.134 The presence of calcium and potassium in addition to the absence of 
sodium may beneficially influence overall dietary quality and engender reduction in CVD 
risk factors, especially hypertension.134 
 
Structure and properties  
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As mentioned previously, the lack of lipid bioaccessibility in almonds due to their 
cell wall structure and properties positively influence CVD risk factors.134 This may 
likely be responsible for the postprandial hypolipidemic effect of almonds as well as for 
weight maintenance or loss demonstrated by an almond-rich diet.134   
 
Aerobic Physical Activity 
Recommendations 
The Physical Activity Guidelines for Americans currently recommends inactivity 
should be avoided as any amount of physical activity (PA) produces some health 
advantages.135 At least 150 minutes of moderate-intensity or 75 minutes of vigorous-
intensity aerobic activity per week or an equivalent combination is the recommendation 
for substantial health advantages in adults (18-64 years old).135 It is specified that aerobic 
activity should be engaged in at least 10-minute bouts and ideally spread throughout the 
week.135 For further and more sizable health benefits, 300 or 150 minutes of moderate 
and vigorous intensity, respectively, or an equivalent combination is recommended for 
adults.135 Muscle strengthening activities encompassing all main muscle groups are 
recommended for adults at least 2 days a week.135 It should be noted that moderate-
intensity is defined as PA that raises one’s breathing and heart rate to some extent (5 or 6 
on a 10 point scale relative to one’s capacity) while vigorous-intensity is defined as PA 
that raises one’s breathing and heart rate to a great extent (7 or 8 on a 10 point scale 
relative to one’s capacity).135 
These recommendations are in line with the American Heart Association (AHA) 
and American College of Sports Medicine joint guidelines for otherwise healthy adults, 
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the AHA and American College of Cardiology joint guidelines for secondary prevention 
of CAD, and the AHA guidelines for primary prevention of stroke and CVD being 30 
minutes of moderate PA most days of the week.42,136 The AHA defines moderate PA as 
40-60% of maximum capacity comparable to a 15 to 20-minute mile involving brisk 
walking.42 
Protective Role in CVD 
 Strong evidence exists linking PA to CVD risk reduction.42 Specifically, 
numerous studies have emphasized the pivotal role of walking in health promotion as 
interventions of walking improve several CVD risk factors.137 A walking intervention is 
favorably suited to a PA prescription as it is low cost, low injury risk, and requires no 
special skills or resources.42,137 
 
Epidemiological Evidence 
Epidemiological evidence indicates slight increases in daily walking is better than 
nothing, with larger improvements extending greater CVD health advantages. Enhanced 
fitness, blood pressure, body composition, and lipid profiles constitute possible short-
term benefits and lower CHD, coronary events, and mortality risk constitute long-term 
benefits.138  
 
Observational Studies 
Observational studies consistently illustrate walking associated with CVD 
endpoints in the long-term.138 PA, including brisk walking, has been demonstrated to 
assist in CVD prevention with increased duration, distance, energy expenditure, 
frequency, and pace associated with larger risk reductions in a broadly dose-dependent 
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manner.10,11,138 Such associations seem to be stronger for ischemic stroke in comparison 
with other outcomes like CHD or hemorrhagic stroke and multiple studies specifically 
suggest less subclinical atherosclerosis is associated with walking pace.10,11 The 
associations of walking volume and intensity with decreased CVD risk are similar in both 
males and females supporting the widely held consensus that walking seems to have 
CVD health advantages in both healthy and patient populations regardless of age or 
sex.138 Walking also has been shown to reduce risks for hypercholesterolemia, 
hypertension, diabetes mellitus, and possibly CHD similarly to iso-energetic expenditures 
of running.139  
 
Intervention Studies 
Intervention trials additionally support evidence from epidemiological and 
observational studies by demonstrating short-term benefits in clinical biomarkers and 
measurements. A recent systematic review and meta-analysis of randomized controlled 
trails on the effects of walking on CVD risk factors suggest that walking interventions 
improve aerobic capacity (3.04 mL/kg/min, 95% CI 2.48 to 3.60), systolic blood pressure 
(− 3.58 mm Hg, 95% CI −5.19 to −1.97), diastolic blood pressure (−1.54 mm Hg, 95% 
CI −2.83 to −0.26), weight (−1.37 kg, 95% CI −1.75 to −1.00), BMI (−0.53 kg/m2, 95% 
CI −0.72 to −0.35), percentage body fat (−1.22%, 95% CI −1.70 to −0.73), and waist 
circumference (−1.51 cm, 95% CI −2.34 to −0.68).137 However, there was no evidence of 
alterations in lipids (TC, HDL, LDL) or waist-to-hip ratio.137 It is interesting to note that 
with a walking intervention, FMD has been demonstrated to improve in sedentary 
middle-aged and older men but not in postmenopausal women.140,141  
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Mechanisms of Action  
PA provides many cardiac benefits including improvement in myocardial oxygen 
supply and contraction as well as decreases in sympathetic activity contributing to better 
electric stability of myocardial cells and vascular benefits which are detailed in Table 
6.142,143 Several CVD risk factors are also amended with regular PA such as blood 
pressure, adiposity, insulin sensitivity, and atherogenic lipoprotein levels.142  
Table 6. Vascular Effects of Physical Activity142 
Aorta 
Aortic stiffness ↓ 
Aortic compliance ↑ (endurance training only) 
Conduit Vessel 
Endothelial vasodilation ↑ 
NO production ↑ 
Oxidative stress ↓ 
Resistance vessel & Microcirculation 
Vasculogenesis by endothelial progenitor cells 
Sensitivity to adenosine ↑ 
Capillary bed Capillary vessel formation ↑ 
Venous circulation Venular capillaries ↑ 
Pulmonary artery 
Endothelial function 
Pulmonary artery pressure ↓ (in chronic heart failure) 
 
One of the key mechanisms of improved vascular health in response to regular PA 
is the augmentation of vascular NO.144 PA is associated with greater flow-mediated shear 
stress which up-regulates eNOS via a complex scheme of intracellular regulation.144 This 
up-regulation of eNOS by PA or increased shear stress is well-supported.144 This 
increased activation of eNOS by PA has also been shown to be a main mechanism of 
endothelial progenitor cell mobilization from the bone marrow which contributes to 
vascular regeneration and repair.144 
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CHAPTER 3 
METHODS 
Participants 
The initial enrollment goal for this study was 50 male participants between 45 and 
60 years of age who were otherwise healthy and sedentary (e.g. fail to meet the Physical 
Activity Guidelines for Americans: 150 minutes/week of moderate-intensity activity, or 
75 minutes/week of vigorous-intensity activity).145 Due to initial low participant accrual, 
the study was expanded to otherwise healthy and sedentary (e.g. sit > 8 hours daily) men 
and postmenopausal women between 20 and 60 years of age. The sample size (n) of 50 
participants was determined through colleague collaboration and a sample size calculator 
tool developed by David Schoenfeld of Harvard University. Recent studies examining 
differing effects of nuts on vascular reactivity provided data for the sample size 
calculations (see Appendix D).146-150 An average difference of means and standard 
deviation in FMD of 2.5 ± 4.34 respectively was estimated using a significance level of P 
= 0.05 and power of 0.8. The calculation estimated n = 372. However, this was a pilot 
study and a n = 50 was decided to be appropriate as a sample size of n = 8-15 per group 
has been shown to be suitable for pilot studies to mirror large clinical trials.151,152   
The inclusion criteria were as follows: otherwise healthy men and post-
menopausal women (20-69 years of age) were considered eligible for the study if they 
routinely sit > 8 hours daily, believe they need to increase their physical activity, 
answered ‘no’ to all questions on the Physical Activity Readiness Questionnaire (PARQ), 
and have constant dosing of a non-nitrate vasoactive medication. The exclusion criteria 
were as follows: individuals who reported chronic disease (e.g. cancer, heart disease, 
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asthma, arthritis, and hypertension), individuals who were unwilling to participate in an 
8-week walking intervention or comply with testing protocols, individuals with reported 
nut or gluten allergies, cigarette use within the past year, food allergies, and specific 
medication use (nitrate vasoactive hypertensive medications, nitroglycerin, beta-blockers, 
and calcium channel blockers), and individuals who measured as hypertensive at the test 
site (blood pressure > 140/90). 
Participants were recruited from the Diocese of the East Valley, Arizona State 
University, Encanto Golf Course, the YCMA, religious groups, parking lots, and 
shopping areas in the Phoenix metropolitan area via listservs, emails, and flyers (see 
Appendix E). Interested participants were directed to complete an online pre-screening 
survey including the Physical Activity Readiness Questionnaire (see Appendix F). Sixty-
four individuals responded to our pre-screening survey conducted through 
SurveyMonkey over a 2-month enrollment period. Of these, 15 individuals met the 
inclusion criteria and were invited to the downtown Phoenix campus of ASU to verify 
eligibility, provide informed consent, and complete a health history questionnaire (see 
Appendices G and H). One participant was excluded due to meeting the exclusion criteria 
(e.g. measured hypertensive at the test site) and two participants opted out before study 
completion, leaving 12 participants (see Figure 1).   
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Figure 1. Attrition Flow Chart 
 
Study Design 
This pilot study represents a placebo-controlled, randomized parallel two-arm trial 
consisting of 12 participants. The study contained the following 2 groups: ALM Group 
consumed whole, raw almonds (2.5 oz daily) and briskly walked 10,000 steps per day 
and CON Group consumed a placebo (4 Tbsp of Speculoos Cookie Butter daily) and 
briskly walked 10,000 steps per day. The independent variable is represented by the type 
of nut product apportioned. The nut products included whole, raw almonds (2.5 oz 
equaling 400 calories) or isocaloric cookie (nut) butter (4 Tbsp equaling 360 calories; 
contains traces of tree nuts) (see Appendix I).153 The raw whole almonds were provided 
by the Almond Board of California and were prepackaged into 2.5 oz servings.  
12 participants (ALM: 2 M & 4 F, CON: 1 M & 5 F)
completed study
1 participant excluded (hypertensive at test site) & 2 participants 
opted out (physical condition & participant burden)
15 participants
met inclusion criteria
64 participants 
via SurveyMonkey responses
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The study was approved by the Arizona State University Institutional Review 
Board before it was initiated (see Appendix J). The study involved four visits to the test 
site at the ASU Nutrition Labs on the Phoenix Downtown Campus over the 8-week study 
period where anthropometrics, blood pressure, body composition, FMD, fitness step test 
and fasting blood samples were taken at each visit. Informed consent was administered at 
visit 1 where participants were apprised of the potential benefits (i.e. possible increased 
fitness level and FMD outcomes if desired) and risks (i.e. possible temporary nausea or 
faintness during the blood draw and possible injury with increased physical activity) of 
study participation. No conflicts of interest were involved in this study and 
confidentiality was maintained by assigning each participant an ID number and removing 
all patient identification factors from the data, keeping files in a locked file cabinet and 
password protecting all electronic files or computers housing files containing identifiable 
information, and blinding principal investigators and laboratory technicians.  
 
Study Protocol 
Visit 1 occurred one-week pre-trail where the participants visited the Arizona 
Biomedical Collaboration building for signed written consent, health history screening, 
gait, anthropometrics (i.e. height and weight), and body composition (Tanita) 
measurement. Participants were given the following: a compliance calendar with 
instructions to record daily steps from the pedometer and to check off when nut products 
(i.e. almonds or cookie butter) were consumed for trial weeks 6-8 (see Appendix K), a 3-
day food record with instructions, and a pedometer with instructions to wear it each day 
for the entire trial. Participants were instructed to restrict their nut and seed consumption 
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(including almond milk) to 2 or less servings per week during the entire trial, excluding 
the study products. Participants were coached to continue their normal dietary and 
physical activity patterns (with the exception of the nut restriction) and not change from 
their usual routine.  
At visit 2 (week 0 or trial baseline), pedometer data was downloaded and 
recorded, the 3-day food record was collected, and the following measures were 
completed: FMD, blood pressure, anthropometrics, body composition, YMCA Bench 
Step Test for Cardiovascular Fitness, and a fasting blood sample. Participants were 
coached to slowly increase step counts to 10,000 steps daily within the next 2 weeks and 
then asked to maintain this step count for the duration of the study. Trial weeks 3-5 
represented the walking phase of the study and measurements demonstrate the benefits of 
solely walking for all study participants.  
Visit 3 (week 5) involved downloading and recording pedometer data, assigning a 
second 3-day food record, dispensing nut products and providing instructions, repeating 
the measurements conducted at visit 2, and giving a $15 gift card. Participants were 
stratified by sex, age, height, weight, BMI, fat percentage, and baseline step count and 
randomly assigned (by coin toss) to receive either 30 individual 2.5 oz packages of raw 
whole almonds or four 14.1 oz jars of cookie (nut) butter. Trial weeks 6-8 represented the 
nut intervention phase of the study and measurements demonstrate the benefits of almond 
consumption in addition to walking for all study participants.  
Visit 4 (week 8) involved downloading and recording pedometer data, collecting 
the second 3-day food record and compliance calendar, repeating the measurements 
conducted at visit 2, and giving a $15 gift card. All 4 visits took place at the ASU 
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Nutrition Labs within the Arizona Biomedical Collaboration (ABC) building on the 
Phoenix Downtown Campus and lasted approximately 45 minutes to 1 hour in length. 
Between all 4 site visits, emails were issued to follow-up, answer questions, and provide 
reminder instructions in regards to all dietary supplements restriction 3 days prior to their 
visit, strenuous exercise restriction 48 hours prior to their visit, and caffeine, alcohol, 
food and drink (except water) restriction 12 hours prior to their visit. See Figure 2 for 
complete overview of study protocol.  
 
 
 
Figure 2. Study Protocol Flow Chart 
 
 
Laboratory Analyses  
FMD and blood pressure measures were conducted at baseline, week 5, and week 
8 by a full-time School of Nutrition and Health Sciences trained, certified sonographer 
(Theresa Jorgensen RDCS, RDMS, RVT). FMD was performed using high resolution 2K 
and Doppler ultrasound (HDI 5000, ATL Philips Ultrasound). The cuff, appropriate to 
the size for the limb, was distally positioned to the ultrasound probe at the brachial artery. 
The cuff was then inflated to  50 mm Hg above systolic arterial pressure for 5 minutes 
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to generate a reactive hyperemic stimulus which is regarded as primarily endothelium 
mediated and NO dependent.154 To ensure accuracy of measurement, probe location was 
recorded for each participant with repeated measures at the same site. To ensure proper 
probe location among tests, visible anatomical landmarks on the ultrasound were used 
(see Appendix L for detailed protocol). 
Fasting venous blood draws were performed at baseline, week 5, and week 8. 
Trained staff (Ginger Hook RN, CDE and Veronica Zamora R.T. (R) (BD) ARRT) 
collected the blood samples using EDTA-coated vacutainers. Whole blood was 
centrifuged to remove the plasma. Plasma samples for total nitrate/nitrite analyses were 
pre-filtered using 30 molecular weight cut-off microcentrifuge filters according to the 
manufacturer’s protocol (Millipore, Billerica, MA) following the Griess method (See 
appendix M; Cat. No. 780001, Cayman Chemical, Ann Arbor, MI). Thiobarbituric acid 
reactive substances (a measure of lipid peroxidation) was analyzed using a commercial 
colorimetric assay kit (Cat. No. 0801192, ZeptoMetrix Corporation, Buffalo, NY) 
following the manufacturer’s instructions (See appendix N). Vitamin E analyses were 
performed by Dr. Kevin McGraw as a food study intervention compliance marker. 
 Anthropometrics (i.e. height and weight), body composition measures, and the 
YMCA Bench Step Test for Cardiovascular Fitness were performed at baseline, week 5, 
and week 8 for a separate study by a graduate researcher (Elizabeth McElaney MS, 
NASM – CPT, CES). As these data were collected for a separate study, the outcomes will 
not be included in this thesis.  
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Statistical Analyses 
The statistical software Statistical Package for the Social Sciences (SPSS) was 
employed. A statistically significant p-value of  0.05 was used and data is presented as 
the mean  SD. If normality was not attained using the Shapiro-Wilk test of normality, 
the data was transformed and the effect sizes were determined. Independent Samples T-
tests were employed to compare variables between groups at baseline and week 5. Paired 
T-tests were used to compare changes within groups over the first 5 weeks. Analysis of 
Covariance (ANCOVA) controlling for baseline and change in steps was used to measure 
changes in variables between groups and multivariate analysis of variance (MANOVA) 
was used to measure changes in FMD between groups from baseline to week 8. 
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CHAPTER 4 
RESULTS 
Twelve participants (6 in ALM group and 6 in CON group) completed the pilot 
study. Verbal affirmation was received from all participants that daily nut products were 
consumed despite 8 of the 12 compliance calendars being incomplete and combined 
alpha-Tocopherol and gamma-Tocopherol measures showing no difference between 
groups for change with a mean of +0.4  0.6 g/ml for the ALM group and a mean of 
+0.5  0.6 g/ml for the CON group (p = 0.470) with an effect size of 0.067.  
There were no differences between participants in each group at baseline as 
illustrated in Table 7. Mean participant age at baseline was 55.5  8.6 y for the ALM 
group and 52.7  10.9 y for the CON group. Additionally, there were no differences 
between participants in either group at week 5 as illustrated in Table 8.  
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Table 7. Participant Characteristics at Baseline 
Variablea ALM CON P VALUE* 
Subjects (M/F) 2 M / 4 F  1 M / 5 F  
Age (y) 55.58.6 52.710.9 0.629 
Weight (kg) 77.211.7 72.88.7 0.482 
Height (cm) 166.210.6 168.57.3 0.667 
Body Fat (%) 33.18.3 34.39.4 0.817 
Fat Free Mass (kg) 51.811.6 47.78.0 0.486 
BMI (kg/m2) 28.04.0 25.61.8 0.217 
Heart Rate, rest (BPM) 73.86.7 72.511.1 0.806 
Pedometer (steps) 82781657 78472672 0.744 
METS (kcal·kg-1·wk-1) 33.220.8 71.752.8 0.128 
Total nitrates and nitrites (µM/L) 56.637.7 57.826.4 0.948 
Blood Pressure Systolic (mmHg) 120.06.5 121.317.6 0.865 
Blood Pressure Diastolic (mmHg) 74.28.1 75.59.5 0.799 
Total Cholesterol (mg/dL) 169.035.6 196.318.4 0.127 
HDL (mg/dL) 52.28.9 56.914.2 0.504 
LDL (mg/dL) 108.533.5 124.622.7 0.352 
Triglycerides (mg/dL) 94.160.6 135.065.4 0.287 
TBARS (nmol MDA/mL) 1.20.5 1.41.0 0.544 
hsCRP (mg/L) 1.61.5 1.61.4 0.915 
a Data is represented as Mean±SD. *p-value represents Independent Samples T-Test. 
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Table 8. Participant Characteristics at Week 5 
Variablea ALM CON P VALUE* 
Subjects (M/F) 2 M / 4 F  1 M / 5 F  
Weight (kg) 76.911.5 73.08.4 0.515 
Body Fat (%) 34.18.3 33.58.9 0.909 
Fat Free Mass (kg) 50.911.3 48.58.4 0.689 
BMI (kg/m2) 27.94.0 25.51.4 0.214 
Heart Rate, rest (BPM) 77.07.1 72.75.7 0.272 
Pedometer (steps) 97292068 104821348 0.472 
Total nitrate and nitrites (µM/L) 37.913.8 34.815.3 0.720 
Blood Pressure Systolic (mmHg) 117.56.9 124.79.8 0.173 
Blood Pressure Diastolic (mmHg) 73.84.2 72.27.9 0.658 
Total Cholesterol (mg/dL) 177.433.8 195.514.4 0.255 
HDL (mg/dL) 55.58.4 57.416.7 0.807 
LDL (mg/dL) 113.329.9 123.519.9 0.502 
Triglycerides (mg/dL) 87.547.4 141.453.8 0.095 
TBARS (nmol MDA/mL) 0.80.5 1.20.6 0.263 
hsCRP (mg/L) 1.81.7 2.23.2 0.787 
a Data is represented as Mean±SD. *p-value represents Independent Samples T-Test. 
 
 
The walking intervention alone (week 0-5) resulted in a change in variables for 
step count of ALM and CON groups combined with a mean of 8063 ± 2132 steps at 
baseline and 10105 ± 1710 steps at week 5 (p=0.022) and total nitrates and nitrites ALM 
and CON groups combined with a mean of 57.2 ± 31.1 µM/L at baseline and 36.3 ± 14.0 
µM/L at week 5 (p=0.052) as illustrated in Table 9. These two changes are not related 
when change was compared with correlation. All other variables including FMD, systolic 
and diastolic blood pressure, total cholesterol, HDL, LDL, triglycerides, TBARS, and 
hsCRP showed no significant change as displayed in Table 9.  
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Table 9. Impact of Walking Intervention Alone in All Participants 
Variablea Baseline Week 5 Paired t-test 
Pedometer (steps) 
FMD (peak %) 
Total nitrates and nitrites (µM/L) 
Blood Pressure Systolic (mmHg) 
Blood Pressure Diastolic (mmHg)  
Total Cholesterol (mg/dL)                       
8063±2132 
6.7±4.6 
57.2±31.1 
120.7±12.7 
74.8±8.5 
182.6±30.5 
10105±1710 
7.2±3.5 
36.3±14.0 
121.1±8.9 
73.0±6.1 
186.5±26.5 
0.022 
0.592 
0.052 
0.926 
0.408 
0.338 
HDL (mg/dL) 54.5±11.6 56.5±12.7 0.196 
LDL (mg/dL) 116.6±28.5 118.4±24.8 0.602 
Triglycerides (mg/dL) 114.6±63.8 114.5±55.9 0.986 
TBARS (nmol MDA/mL) 1.30±0.79 0.99±0.57 0.181 
hsCRP (mg/L) 1.59±1.35 2.03±2.49 0.260 
a Data is represented as Mean±SD; n = 12. Data was analyzed by paired t-tests. All data normally 
distributed. 
 
The additive effect of the walking intervention with the nut product (week 5-8) 
resulted in significant differences in total cholesterol with a -11.0  10.5 and +3.3  15.8 
mg/dL (p=0.043) change in the ALM and CON group respectively and LDL with a -11.5 
 7.5 and +0.5  13.7 mg/dL (p=0.025) change in the ALM and CON group respectively 
(see Table 10). These significant differences illustrate a 6.2% decrease of total cholesterol 
in the ALM group and a 10.2% decrease in LDL in the ALM group. There was a trend 
for TBARS to lower in the ALM group versus the CON group (-0.2  0.8 and +0.3  0.6 
nmol MDA/mL (p=0.099) respectively) with a large effect size of 0.304 but this did not 
reach statistical significance (see Table 10). The significant difference in total cholesterol 
and LDL and the trend in TBARS as seen from week 5 to 8 is illustrated in Figures 3, 4, 
and 5 respectively. Additionally, there was a trend for steps to increase in the ALM group 
and a trend for steps to decrease in the CON group (+676  1643 and -1416  1569 steps 
(p=0.079)) with a large effect size of 0.304.  
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Table 10. Additive Effect of Walking + Snack 
Variablea  Week 5
b Week 8c Change 
P-value 
(effect size) 
Pedometer (steps)     
ALM 9729±2068 10404±1348 +6761643 0.079 
CON 10482±1348 9066±2347 -14161569 (0.304) 
FMD (peak %)     
ALM 8.4±4.4 7.3±5.1 +0.41.2 0.882 
CON 6.0±2.0 5.7±1.5 -0.31.4 (0.003) 
Total nitrates and nitrites 
(µM/L) 
    
ALM 37.9±13.8 45.0±17.8 +7.228.7 0.614 
CON 34.8 ±15.3 44.1±26.1 +9.429.1 (0.033) 
Blood Pressure Systolic 
(mmHg) 
    
ALM 117.5±6.9 115.8±10.9 -1.75.8 0.114 
CON 124.7±9.8 118.5±6.6 -6.28.2 0.283 
Blood Pressure Diastolic 
(mmHg) 
    
ALM 73.8±4.2 72.3±9.0 -1.57.6 0.843 
CON 72.2±7.9 74.8±8.5 +2.75.9 0.005 
Cholesterol (mg/dL)   
  
ALM 177.4±33.8 166.4±34.7 -11.010.5 0.043 
CON 195.5±14.4 198.8±20.7 +3.315.8 (0.420) 
HDL (mg/dL)    
  
ALM 55.5±8.44 54.4±8.01 -1.15.56 0.287 
CON 57.4±16.7 61.3±16.8  +3.86.7 (0.140) 
LDL (mg/dL)    
  
ALM 113.3±29.9 101.8±30.2 -11.57.5 0.025 
CON 123.5±19.9 124.0±24.3 +0.513.7 (0.485) 
Triglycerides (mg/dL)   
  
ALM 87.5±47.4 105.5±81.7 +18.038.9 0.136 
CON 141.4±53.8 147.7±69.1 +6.329.1 (0.256) 
TBARS (nmol MDA/mL)   
  
ALM 0.8±0.5 0.6±0.4 -0.20.8 0.099 
CON 1.2±0.6 1.4±0.7 +0.30.6 (0.304) 
hsCRP (mg/L)    
  
ALM 1.8±1.8 1.7±1.7 -0.10.4 0.388 
CON 2.2±3.2 1.1±1.3 -1.12.0 (0.094) 
a Data is represented as Mean±SD; n = 6 per group with exception of FMD with n = 5 for the ALM 
group. P-value and effect size represent ANCOVA analyses controlling for baseline value and change 
in steps. All data normally distributed except for hsCRP which is near normal (could not be normalized 
because transformation worsened normality). Inverse transformation was used to normalize TBARS 
and removal of an outlier (2.8 SD away from mean) was used to normalize FMD.bWalking only; 
cWalking + almond or cookie butter. 
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Figure 3. Significant Change in Total Cholesterol During Week 5-8 
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Figure 4. Significant Change in LDL During week 5-8 
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 Figure 5. Trend in Oxidative Stress Biomarker (TBARS) During week 5-8 
 
There were no significant differences seen in markers of the other plasma lipid 
profile measures, plasma inflammatory cytokines, blood pressure regulation, or step 
count as shown in Table 10. All data presented in Table 10 are normally distributed 
except for hsCRP. The biomarker hsCRP could not be normalized because transformation 
worsened normality. Inverse transformation was used to normalize TBARS and removal 
of an outlier (2.8 standard deviations away from the mean) was used to normalize FMD.  
Although FMD increased in the ALM group from baseline to week 8, there were 
no significant differences seen in FMD from baseline with a mean of 6.9  6.1 and 6.3  
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2.9 to week 8 with a mean of 7.3  5.1 and 5.7  1.5 in the ALM and CON group 
respectively (p=0.382, effect size = 0.077).  
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CHAPTER 5 
DISCUSSION 
This pilot study represents a randomized, parallel, two-arm study comparing the 
combined effect of daily almond ingestion (2.5 ounces) and brisk walking (10,000 steps 
per day) versus the combined ingestion of an isocaloric placebo (4 Tbsp cookie butter) 
and brisk walking (10,000 steps per day) in sedentary adults. The possible synergistic 
effect of almond ingestion in conjunction with a walking intervention on CVD markers 
was examined. The main biomarkers investigated were FMD (peak %), total nitrates and 
nitrites (µM/L), blood pressure (mmHg), total cholesterol (mg/dL), HDL (mg/dL), LDL 
(mg/dL), triglycerides (mg/dL), TBARS (nmol MDA/mL), and hsCRP (mg/L). 
The additive effect of the daily walking intervention with almond consumption 
resulted in significant differences in total cholesterol and LDL. There was a trend for 
TBARS to decrease in the ALM group versus the CON group with a large effect size of 
0.304 but this did not reach statistical significance. There were no significant differences 
seen in FMD, total nitrates and nitrites, blood pressure, HDL, triglycerides, and hsCRP. 
Additionally, there was a trend for steps to increase in the ALM group and a trend for 
steps to decrease in the CON group with a large effect size of 0.304. 
Due to the small sample size (n=12) and lower statistical power, statistical 
findings may be misleading as the dietary associations with CVD risk markers might 
have been blunted. There is also the possibility that only large differences could be 
detected in measures as opposed to being able to detect small effects had a larger sample 
size been recruited. Therefore, the trend for TBARS with a large effect size suggests a 
moderate to high practical significance. The trend in step count to increase in the ALM 
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and decrease in the CON group could reflect the inevitable unpredictable participant 
compliance.  
 The results of significant differences in total cholesterol and LDL and no 
significant difference in HDL and triglycerides are consistent with the plethora of well-
established empirical evidence of the effects of almond ingestion.155 A recent meta-
analysis of RCTs including normolipidemic, hyperlipidemic, prediabetic and/or diabetic, 
and obese individuals concluded that almond ingestion reduces total cholesterol with a 
strong trend to lower LDL but HDL and triglycerides remain largely unaffected.156 
However, some studies have conversely shown improvements in HDL and 
triglycerides.26,157 The inclusion of postmenopausal women may have confounded HDL 
results. Estrogen is believed to have cardio-protective effects by preserving vascular 
health and function specifically in regards to protecting the flexibility of blood vessels to 
adapt to blood flow.44 Endogenous estrogen declines with menopause, therefore, 
increasing CVD risk indicated by a substantial rise in LDL in the perimenopause period 
and continuing up to the age of 60 years at least.158 Interestingly, prospective and cross-
sectional evidence demonstrate only a slight decrease in HDL at the time of 
menopause.158 HDL levels in females carry on to be higher than males for 30 years after 
menopause at the minimum and thus may have impacted results of this study.158 The 
significant difference in LDL is in agreement with dose response findings in previous 
studies of a 1% decrease in LDL for each 7-8 g of almonds.25 This pilot study 
demonstrated a 10.2% decrease in LDL in the ALM group vs the CON per 70.88 g/d of 
almonds or a 1% decrease in LDL for each 7 g of almonds.  
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While there is epidemiological evidence that indicates a MUFA and tocopherols-
enriched diet lowers blood pressure and clinical evidence that specifically an almond-
enriched diet can reduce blood pressure, the study results did not reflect this effect.131 
However, additional research corroborates the results of a lack of significant blood 
pressure change.146 In the present pilot study a lack of change in blood pressure is 
expected due to the following: participants were not extremely sedentary even though 
they met the inclusion criteria, participants only had a 25% increase in steps from 
baseline to week 5 and that more or less sustained until week 8, and NOx and FMD had 
no significant changes. Almond ingestion has been demonstrated to influence some but 
not all inflammatory and oxidative stress markers which are correspond with the mixed 
results of a trend for TBARS to decrease in the ALM group and no significant difference 
in hsCRP.111,131 It is supported that antioxidant effects of almonds may be seen in 
individuals with heightened oxidative stress.111 Furthermore, TBARS as a biomarker of 
oxidative stress is questionable as this measure has low repeatability, poor 
reproducibility, and lacks specificity and full validation data in biological fluids.157  
Almonds being rich in arginine and alpha-tocopherol are anticipated to increase 
NO bioavailability and FMD in theory.131 However, the result of no significant difference 
in total plasma nitrates and nitrites is consistent with recent studies.146,131 The presence of 
additional eNOS-independent origins of serum nitrate and nitrites may likely explain the 
results.160 NO concentrations are not solely dictated by endogenous NO by way of NO 
synthases.160 Exogenous sources including the diet (i.e. vegetables), cigarette smoke, and 
medications (i.e. nitrovasodilators) and additional endogenous sources including oral and 
intestinal bacteria (i.e. nitrate reductase enzymes) also contribute to the NO storage 
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pool.87,160 Therefore, dietary and environmental factors as well as the limitation of not 
controlling for antiseptic mouthwash which reduces oral nitrite production (90%, P < 
0.001) and serum nitrite concentrations (25%, P = 0.0001) may have skewed total nitrates 
and nitrites results.161 Measuring NO is challenging as the free radical has a 1 
microsecond to 2 milliseconds of half-life and a diffusion reach of approximately 0.1 
m.87 Because of this, the metabolic products of NO (nitrite and nitrate) are commonly 
used as accepted surrogate markers due to their longer half-lives of 11-42 minutes and 5-
8 hours respectively.87 However, recent research refute that nitrate and/or NOx are 
beneficial markers and suggest NOx, an assay of the total amount of nitrates and nitrites, 
is inaccurate in acute NO testing.162,163 The findings show NOx concentrations remain 
unchanged with pharmacological alteration of the L-arginine: NO pathway, sensitivity of 
serum nitrite levels indicate acute alterations in regional eNOS activity, acetylcholine-
induced blood flow reactions and serum nitrite augmentation are nearly solely NOS 
mediated, and serum nitrite concentrations are vasodilator-inactive.163 Accordingly, there 
is strong evidence for nitrite specificity as a marker for NO production as it more 
accurately reflects acute eNOS activity fluctuations in the human forearm circulation.161 
Hence, nitrite alone has been suggested as a NO marker.163 NOx over solely nitrite was 
employed as a biomarker in this study due to the fasted state of the participants making it 
unlikely to be able to detect measurable levels of plasma nitrite with a half-life of 11-42 
minutes.87 The questionable accuracy of NOx used also may have influenced data and 
explain the lack of significant change for total nitrates and nitrites.  Even though as much 
as 70% of plasma nitrite is from eNOS, additionally dietary and environmental factors 
may have influenced total nitrates and nitrites results.160  
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Again, it would be predicted in theory that almond consumption increases FMD 
but no significant difference was shown.131 Very few studies have examined almond 
consumption with the outcome measure of FMD but those that have report mixed results 
(i.e. no effect, partial effect, full effect).46,131,132 There are many factors that may have 
confounded such results including food, drugs, temperature, sympathetic stimuli, etc.164 
Subjects were instructed to avoid all dietary supplements, strenuous exercise, and 
caffeine, food, and drink (except water) 3 days, 48 hours, and 12 hours prior to visits, 
however, patient noncompliance is always a possibility.164 Current guidelines recommend 
all vasoactive drugs be withheld a minimum of four half-lives prior to testing if possible, 
however, there is evidence that may suggest otherwise.164 Gokce et. al. demonstrated that 
healthy subjects randomized to a single oral dose of felodipine, enalapril, metoprolol, or a 
placebo and CAD patients on prescribed antianginal and/or antihypertensive drugs, all 
common non-nitrate vasoactive medications, resulted in no significant effect on brachial 
artery dilation.165 In light of this evidence and greater methodology practicality, 
participants on a constant dose of non-nitrate vasoactive drugs were included in the study. 
FMD results may have been confounded by not withholding all vasoactive drugs four 
half-lives prior to testing and/or may have been confounded if participants were 
noncompliant with constant dosing of non-nitrate vasoactive drugs during the entirety of 
the study. Additionally, significant improvements in FMD are seen when parallel-group 
study designs have 40-60 subjects typically with baseline mean FMD measures for 
asymptomatic adults being 6.1  3.2.166,167 In a study of such size, an absolute FMD 
change of 1.5-2% is the minimal statiscially significant improvement required to be able 
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to detect a significant change with intervention.166 Therefore, the FMD results may have 
been blunted due to the small sample size (n = 12) and lower statistical power. 
Overall, almond ingestion had an advantageous effect over walking. The impact 
of a 25% increase in steps during the walking intervention alone in all participants had no 
effect on any CVD biomarkers with the exception of a decrease in total nitrates and 
nitrites. This change in variable was not expected and may be due to the possibility that 
study participants had diets high in L-arginine (i.e. seeds and nuts) prior to study 
initiation. A nut restriction commenced with study initiation. So, if participants went 
from high nut and seed consumption to little to no consumption this could explain the 
change in this variable. A 25% increase in steps does not represent a substantial increase 
which therefore may have limited the effectiveness of the walking intervention alone.  
Participant compliance for the walking intervention alone is demonstrated by the 
25% increase in step count by participants of which the compliance calendars support as 
well. Verbal affirmations, compliance calendars, and tocopherols measures were 
employed to gauge participant compliance for the almond intervention in addition to the 
walking intervention.  While 8 of the 12 compliance calendars were incomplete, verbal 
affirmation was received from all participants that daily nut products were consumed. 
The combined alpha-Tocopherol and gamma-Tocopherol measures showed no difference 
between groups for change, with a mean of +0.4  0.6 g/ml for the ALM group and a 
mean of +0.5  0.6 g/ml for the CON group (p = 0.470) which illustrates compliance in 
both groups. The fat in the cookie butter is from palm and canola oil. Both of these oils 
contain between approximately 16 to 18 mg per 100 g of vitamin E, therefore, the 
placebo of 4 tablespoons of cookie butter can be estimated to contain 4 mg of vitamin 
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E.114 Even though the 2.5 oz almond intervention contained 18.85 mg of vitamin E, 
around 16.5% of vitamin E is released following duodenal digestion whereas up to 90% 
of vitamin E is absorbed from oils.127,168,169 Hence, the two food interventions provide 
comparable amounts of vitamin E. For this reason, the cookie butter used constitutes an 
ideal placebo controlling for vitamin E. 
The current study had many limitations as stated previously but it also had many 
strengths. While the pilot study did not represent the most ideal and controlled 
conditions, it did reproduce real-world circumstances with home-prepared foods as the 
background diet and used almonds as the supplemental food intervention which are easily 
available and commonly consumed by the public in a daily dose (2.5 oz) that is 
reasonable for realistic implementation. 
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CHAPTER 6 
CONCLUSIONS & RECOMMENDATIONS 
Conclusions 
Total cholesterol and LDL cholesterol improve favorably for the ALM versus 
CON group with statistically significant differences seen, in addition to a trend of 
improvement in MDA with a large effect size indicating possible significance if the study 
had been adequately powered. Hypothesis 1 being that daily almond ingestion along with 
brisk walking will act synergistically to improve blood pressure regulation was not 
supported as there was no evidence of a statistically significant improvement in FMD, 
total NO production, or systolic and diastolic blood pressure. Hypothesis 2 being that 
daily almond ingestion along with brisk walking will act synergistically to decrease CVD 
risk was partially supported as there was evidence of statistically significant 
improvements in total cholesterol and LDL but not HDL or triglycerides, a non-
statistically significant trend of improvement in the oxidative stress biomarker MDA but 
no evidence of statistically significant improvement of the plasma inflammatory cytokine 
hsCRP. 
In the present study it has been shown that an almond-enriched diet improves 
lipid profiles and may potentially ameliorate oxidative stress while daily brisk walking 
alone had no positive effect on CVD risk in otherwise healthy sedentary adults. This 
simple, cost-effective, and manageable diet strategy of the incorporation of 2.5 oz of 
almonds in the daily diet can benefit a substantial portion of the population which would 
otherwise be at increased risk of CVD. 
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Recommendations 
Further research that additionally explores the topic at hand is recommended to 
improve understanding of the influence of almonds on CVD risk, particularly adding to 
the body of knowledge on the effects of almonds and mechanism of action on lipids and 
oxidative stress. It is suggested to include additional measurements in regard to LDL 
particle size and oxidative stress. While the walking intervention alone showed no effect, 
sole examination of a similar almond intervention, possibly with the addition of almond 
butter, is proposed. Recruitment of a larger and more focused sample (i.e. only males 
and/or only middle-aged individuals) may be necessary to capture stronger conclusions 
that are adequately powered. A 3-week almond intervention interval is a rather short 
period to influence some CVD risk biomarkers so employment of a longer duration of an 
almond intervention is recommended. 
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3-Day Dietary Food Log Instructions 
 
1. Fill in the 3-day dietary food log over the span of 3 consecutive days including 2 
week days and 1 weekend days. 
 
2. Please record ALL food and drinks consumed throughout each 24-hour period. 
Even if it is a handful of chips or a few pieces of candy. 
 
3. Be as specific as you can about the food type and amounts. 
 
4. If the food is a combination food (i.e. a sandwich), include all contents of the 
meal including any condiments or sauces consumed and the amount of each 
ingredient. 
 
5. Record the amount in the way that it is ordinarily measured or by using the 
portion size worksheet attached. 
 
6. Include the brand name when applicable or if the meal is not prepared by you, be 
as specific as possible with the preparation methods used (i.e. fried, baked, 
sautéed in oil).  
 
7. Please be honest and be precise.  
 
  Sample Log 
 
Time Food Item Amount Description 
e.g. 9am e.g. banana Give as tsp, tbsp, cups, oz, 
weight, or portion 
Include type of food, brand 
name, or restaurant 
6:30 am English Muffin 1 Muffin Whole wheat, Thomas 
6:30 am Banana 1 Medium Fruit  
6:30 am Peanut butter 2 tbsp Low-fat JIFF 
9:30 am Yogurt 6 oz Low-fat Vanilla, Dannon 
9:30 am Granola ½ C Nature Valley 
12:30 pm Spinach 3 C  
12:30 pm Tomato ½ C  
12:30 pm Tofu 3 oz Firm 
12:30 pm Balsamic 
Vinaigrette  
2 tbsp Kraft 
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3-Day Food Log (Day 1) 
ID#  
Da te  
 
 
Time Food Item Amount Description 
e.g. 9am e.g. banana Give as tsp, tbsp, cups, oz, weight, or 
portion 
Include type of food, brand 
name, or restaurant 
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         3-Day Food Log (Day 2) 
ID#  
Da te  
 
 
Time Food Item Amount Description 
e.g. 9am e.g. banana Give as tsp, tbsp, cups, oz, weight, or 
portion 
Include type of food, brand 
name, or restaurant 
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        3-Day Food Log (Day 3) 
ID#  
Da te  
 
 
Time Food Item Amount Description 
e.g. 9am e.g. banana Give as tsp, tbsp, cups, oz, weight, or 
portion 
Include type of food, brand name, 
or restaurant 
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Nutrient Unit 1Value per 100 g 
Data 
points 
Std. Error 2.5 oz = 70.88g 
Proximates 
    
Water g 4.41 90 0.219 3.13 
Energy kcal 579 -- -- 410 
Energy kJ 2423 -- -- 1717 
Protein g 21.15 91 0.117 14.99 
Total lipid (fat) g 49.93 90 0.286 35.39 
Ash g 2.97 90 0.04 2.1 
Carbohydrate, by 
difference 
g 21.55 -- -- 15.27 
Fiber, total dietary g 12.5 89 0.295 8.9 
Sugars, total g 4.35 -- -- 3.08 
Sucrose g 3.95 93 0.212 2.8 
Glucose (dextrose) g 0.17 93 0.035 0.12 
Fructose g 0.11 93 0.04 0.08 
Lactose g 0 93 0 0 
Maltose g 0.04 93 0.02 0.03 
Galactose g 0.07 88 0.021 0.05 
Starch g 0.72 4 0.101 0.51 
Minerals 
     
Calcium, Ca mg 269 89 7.668 191 
Iron, Fe mg 3.71 89 0.139 2.63 
Magnesium, Mg mg 270 88 1.371 191 
Phosphorus, P mg 481 88 6.308 341 
Potassium, K mg 733 88 16.386 520 
Sodium, Na mg 1 85 0.467 1 
Zinc, Zn mg 3.12 86 0.062 2.21 
Copper, Cu mg 1.031 86 0.05 0.731 
Manganese, Mn mg 2.179 88 0.075 1.544 
Selenium, Se µg 4.1 26 2.447 2.9 
Vitamins 
     
Vitamin C, total 
ascorbic acid 
mg 0 49 0 0 
Thiamin mg 0.205 85 0.009 0.145 
Riboflavin mg 1.138 88 0.115 0.807 
Niacin mg 3.618 88 0.15 2.564 
Pantothenic acid mg 0.471 88 0.025 0.334 
Vitamin B-6 mg 0.137 47 0.006 0.097 
Folate, total µg 44 41 6.482 31 
Folic acid µg 0 -- -- 0 
Folate, food µg 44 41 6.482 31 
Folate, DFE µg 44 -- -- 31 
Choline, total mg 52.1 -- -- 36.9 
Betaine mg 0.5 5 0.051 0.4 
Vitamin B-12 µg 0 -- -- 0 
Vitamin B-12, added µg 0 -- -- 0 
Vitamin A, RAE µg 0 -- -- 0 
Retinol µg 0 -- -- 0 
Carotene, beta µg 1 26 0.676 1 
Carotene, alpha µg 0 9 0 0 
Cryptoxanthin, beta µg 0 8 0 0 
Vitamin A, IU IU 2 -- -- 1 
Lycopene µg 0 8 0 0 
Lutein + zeaxanthin µg 1 8 0 1 
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Nutrient Unit 1Value per 100 g 
Data 
points 
Std. Error 2.5 oz = 70.88g 
Vitamin E (alpha-
tocopherol) 
mg 25.63 90 0.29 18.17 
Vitamin E, added mg 0 -- -- 0 
Tocopherol, beta mg 0.23 90 0.071 0.16 
Tocopherol, gamma mg 0.64 90 0.07 0.45 
Tocopherol, delta mg 0.07 88 0.042 0.05 
Vitamin D (D2 + D3) µg 0 -- -- 0 
Vitamin D IU 0 -- -- 0 
Vitamin K 
(phylloquinone) 
µg 0 8 0 0 
Lipids 
     
Fatty acids, total 
saturated 
g 3.802 -- -- 2.695 
4:00 g 0 -- -- 0 
6:00 g 0 -- -- 0 
8:00 g 0 4 0 0 
10:00 g 0 68 0 0 
12:00 g 0 67 0 0 
13:00 g 0 4 0 0 
14:00 g 0.003 90 0.002 0.002 
15:00 g 0 76 0 0 
16:00 g 3.083 90 0.03 2.185 
17:00 g 0.004 88 0.002 0.003 
18:00 g 0.704 90 0.027 0.499 
20:00 g 0.007 90 0.003 0.005 
22:00 g 0.001 82 0 0.001 
24:00:00 g 0 4 0 0 
Fatty acids, total 
monounsaturated 
g 31.551 -- -- 22.362 
14:01 g 0 71 0 0 
15:01 g 0 66 0 0 
16:1 undifferentiated g 0.239 90 0.004 0.169 
16:1 c g 0.227 28 -- 0.161 
16:1 t g 0.012 28 -- 0.009 
17:01 g 0.013 84 0.009 0.009 
18:1 undifferentiated g 31.294 90 0.284 22.18 
18:1 c g 31.294 33 -- 22.18 
18:1 t g 0 47 0 0 
20:01 g 0.005 85 0.003 0.004 
22:1 undifferentiated g 0 4 0 0 
24:1 c g 0 4 0 0 
Fatty acids, total 
polyunsaturated 
g 12.329 -- -- 8.738 
18:2 undifferentiated g 12.324 90 0.177 8.735 
18:2 n-6 c,c g 12.32 61 0.269 8.732 
18:2 CLAs g 0.002 7 0.001 0.001 
18:2 t not further 
defined 
g 0.003 58 0.002 0.002 
18:3 undifferentiated g 0.003 90 0.002 0.002 
18:3 n-3 c,c,c (ALA) g 0.003 67 0.001 0.002 
18:3 n-6 c,c,c g 0 67 0 0 
18:04 g 0 1 -- 0 
20:2 n-6 c,c g 0.002 80 0.001 0.001 
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Nutrient Unit 1Value per 100 g 
Data 
points 
Std. Error 2.5 oz = 70.88g 
20:3 undifferentiated g 0 56 0 0 
20:4 undifferentiated g 0 4 0 0 
20:5 n-3 (EPA) g 0 4 -- 0 
22:5 n-3 (DPA) g 0 4 -- 0 
22:6 n-3 (DHA) g 0 4 0 0 
Fatty acids, total trans g 0.015 -- -- 0.011 
Fatty acids, total trans-
monoenoic 
g 0.012 -- -- 0.009 
Cholesterol mg 0 2 -- 0 
Stigmasterol mg 4 82 0.75 3 
Campesterol mg 5 82 0.458 4 
Beta-sitosterol mg 130 68 6.608 92 
Amino Acids 
    
Tryptophan g 0.211 -- -- 0.15 
Threonine g 0.601 -- -- 0.426 
Isoleucine g 0.751 -- -- 0.532 
Leucine g 1.473 -- -- 1.044 
Lysine g 0.568 -- -- 0.403 
Methionine g 0.157 -- -- 0.111 
Cystine g 0.215 -- -- 0.152 
Phenylalanine g 1.132 -- -- 0.802 
Tyrosine g 0.45 -- -- 0.319 
Valine g 0.855 -- -- 0.606 
Arginine g 2.465 -- -- 1.747 
Histidine g 0.539 -- -- 0.382 
Alanine g 0.999 -- -- 0.708 
Aspartic acid g 2.639 -- -- 1.87 
Glutamic acid g 6.206 -- -- 4.399 
Glycine g 1.429 -- -- 1.013 
Proline g 0.969 -- -- 0.687 
Serine g 0.912 -- -- 0.646 
Other 
     
Alcohol, ethyl g 0 -- -- 0 
Caffeine mg 0 -- -- 0 
Theobromine mg 0 -- -- 0 
Flavonoids 
    
Anthocyanidins 
    
Cyanidin mg 2.46 8 0.58 1.74 
Petunidin mg 0 8 0 0 
Delphinidin mg 0 8 0 0 
Malvidin mg 0 8 0 0 
Pelargonidin mg 0 8 0 0 
Peonidin mg 0 8 0 0 
Flavan-3-ols 
    
(+)-Catechin mg 1.3 12 0.33 0.9 
(-)-Epigallocatechin mg 2.6 3 0.31 1.8 
(-)-Epicatechin mg 0.6 12 0.1 0.4 
(-)-Epicatechin 3-
gallate 
mg 0 4 0 0 
(-)-Epigallocatechin 3-
gallate 
mg 0 2 -- 0 
(+)-Gallocatechin mg 0 4 0 0 
Flavanones 
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Nutrient Unit 1Value per 100 g 
Data 
points 
Std. Error 2.5 oz = 70.88g 
Eriodictyol mg 0.2 8 0.06 0.2 
Hesperetin mg 0 4 0 0 
Naringenin mg 0.4 51 0.05 0.3 
Flavones 
     
Apigenin mg 0 8 0 0 
Luteolin mg 0 4 0 0 
Flavonols 
     
Isorhamnetin mg 2.6 47 0.27 1.9 
Kaempferol mg 0.4 47 0.04 0.3 
Myricetin mg 0 8 0 0 
Quercetin mg 0.4 16 0.11 0.3 
Isoflavones 
    
Daidzein mg 0 2 -- 0 
Genistein mg 0 2 -- 0 
Glycitein mg 0 1 -- 0 
Total isoflavones mg 0.01 2 -- 0.01 
Formononetin mg 0 1 -- 0 
Coumestrol mg 0.02 1 -- 0.01 
Proanthocyanidin 
    
Proanthocyanidin 
dimers 
mg 9.3 17 3.16 6.6 
Proanthocyanidin 
trimers 
mg 7.6 17 2.71 5.4 
Proanthocyanidin 4-
6mers 
mg 27.4 17 12.67 19.4 
Proanthocyanidin 7-
10mers 
mg 28.2 17 10.93 20 
Proanthocyanidin 
polymers (>10mers) 
mg 80.3 8 28.09 56.9 
Nutrient data obtained from the USDA National Nutrient Database for Standard Reference, Release 28 
(2015), slightly revised May 2016 
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APPENDIX CA  
SUMMARY OF EFFECTS OF ALMONDS ON CHOLESTEROL
  87 
 
 
 
 
 
  88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  89 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  90 
 
 
 
 
 
 
 
A Data obtained from Musa-Veloso K, Paulionis L, Poon T, Lee HY. The effects of 
almond consumption on fasting blood lipid levels: a systematic review and meta-analysis 
of randomised controlled trials. Journal of Nutritional Science. 2016;5. 
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APPENDIX D 
SUMMARY OF EFFECTS OF ALMONDS ON OXIDATIVE STRESS
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APPENDIX E 
SAMPLE SIZE CALCULATION
  94 
Author Year FMD N per 
grp 
Calculated 
n per grp 
Age 
range 
Subject state Test 
Chen et 
al. 
2015 .6 ± 
3.5 
25 536 61.8 ± 
8.6 
Proven CAD (M/F) Randomized 
control 
crossover trial 
(almonds) 
West et 
al. 
2012 .83 ± 
3.3 
27 250 48 ± 
1.5 
Elevated LDL (≥ 
2.86 mmol/L); 
otherwise 
healthy/nonsmokers 
(M/F) 
Randomized 
crossover 
controlled-
feeding study 
(pistachios) 
Kasliwal 
et al. 
2015 2.5 ± 
5.5 
27 77 39.8 ± 
8.1 
Mild dyslipidemia 
and no DM/CVD 
(M/F) 
Open label, 
randomized 
parallel group 
study 
(pistachios) 
West et 
al. 
2010 2.1 ± 
3.8 
12 53 49.3 ± 
1.7 
hypercholesterolemic 
(M/F) 
Randomized, 
crossover 
study 
(walnut/flax 
oil) 
Orem et 
al. 
2013 6.6  
± 5.6 
21 13 44.6 ± 
10.4 
hypercholesterolemic 
(M/F) 
Double control 
sandwich 
model 
(hazelnuts) 
Average  2.5 ± 
4.34 
23 186 48.7 ± 
6.06 
  
All data represented as means ±SD; FMD = flow-mediated dilation; CAD = coronary artery disease; M = 
male. F = female; LDL = low density lipoprotein; DM = diabetes mellitus; CVD = cardiovascular disease 
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APPENDIX F 
RECRUITMENT ADVERTISEMENTS
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APPENDIX G 
SURVEYMONKEY SCREENING SURVEY
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APPENDIX H  
INFORMED CONSENT 
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APPENDIX I  
HEALTH HISTORY QUESTIONNAIRE
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APPENDIX J 
COOKIE BUTTER & ALMOND NUTRITION LABEL COMPARISON
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APPENDIX K  
IRB APPROVAL
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APPENDIX L  
COMPLIANCE CALENDAR
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APPENDIX M  
FLOW-MEDIATED DILATION PROTOCOL
  114 
Endothelium-dependent dilation of the brachial artery will be measured by B-
mode ultrasound (Terason u3300+TM, Burlington MA) using guidelines set forth by the 
Brachial Artery Reactivity Task Force. Participants will be asked to lie quietly for 15 
minutes on the ultrasound table before baseline images are obtained for 30 seconds from 
the participant’s non-dominant arm. Simultaneous ultrasound images (B-mode) and 
Doppler waveforms will always be recorded. Subsequently, an appropriately sized blood 
pressure cuff will be wrapped around the patient’s forearm. After the baseline images are 
acquired, the blood pressure cuff will be rapidly inflated using a rapid-cuff inflator 
(Hokanson) on the participant’s forearm to >200mmHg for 5 minutes. Thirty seconds 
prior to cuff release, imaging of the brachial artery will commence. At 5 minutes 
following cuff inflation, the cuff will be rapidly deflated and arterial images will be 
recorded for up to 5 minutes. Images that are obtained will be analyzed by a blinded 
researcher using a previously validated, brachial artery edge-detection software. Intra-
class correlation coefficients in our lab for baseline and peak diameter are 0.994 and 
0.995 respectively (Chronbach α = 0.976). 
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APPENDIX N  
NITRIC OXIDE ASSAY PROTOCOL
  116 
1. Add 200 μl of water or Assay Buffer to the blank wells. Do not add any other reagents 
to these wells.  
2. Add up to 80 μl of sample or sample dilutions to the wells in a pattern you choose. The 
final volume must be adjusted to 80 μl using the Assay Buffer solution. NOTE: Plasma 
samples should be assayed with no more than 40 μl when undiluted samples are used 
(Samples which have been diluted 1:2 or greater can use up to 80 μl in the assay). 
Caution should be taken when pipetting plasma samples to ensure no bubbles enter to the 
well as this will lead to erroneous results.  
3. Add 10 μl of the Enzyme Cofactor Mixture (Item No. 780012) to each of the wells 
(standards and unknowns).  
4. Add 10 μl of the Nitrate Reductase Mixture (Item No. 780010) to each of the wells 
(standards and unknowns).  
5. Cover the plate with the plate cover and incubate at room temperature for one hour. 
NOTE: This incubation time should be increased to two hours when assaying tissue 
culture medium, and increased to three hours when assaying plasma or tissue nitrate + 
nitrite concentrations. It is not necessary to shake the plate during incubation.  
6. After the required incubation time, add 50 μl of Griess Reagent R1 (Item No. 780018) 
to each of the wells (standards and unknowns).  
7. Immediately add 50 μl of Griess Reagent R2 (Item No. 780020) to each of the wells 
(standards and unknowns).  
8. Allow the color to develop for 10 minutes at room temperature. It is not necessary to 
cover the plate. NOTE: The 10 minute incubation is optimal for color development. 
However, if the plate has been left to develop for longer time periods the data is still 
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valid, provided the Griess Reagents have been added to the standard curve and 
unknowns at the same time. Developing the standard curve at the same time as the 
unknowns ensures the presence of an accurate control.  
9. Read the absorbance at 540 nm or 550 nm using a plate reader.  
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APPENDIX O  
TBARS ASSAY PROTOCOL
  119 
 
Allow all reagents to reach room temperature before use. SDS Solution will take at least 
one hour if stored at 2-8C. Heating the SDS Solution at 37˚C briefly will redissolve 
precipitated SDS. SDS Solution can then be stored at room temperature.  
 
Step 1: Collect EDTA plasma (lavender top Vacutainer®).  
Step 2: Label two sets of disposable microcentrifuge tube with the standard number or 
sample identification. Poke a hole in the lid of each tube. 
Step 3: Add 30 l sample or standard (prepare malondialdehyde standard curve as 
described in the protocol) to properly labeled tube.  
Step 4: Add 30 l SDS Solution to each tube and swirl to mix.  
Step 5: Add 750 ml TBA/Buffer Reagent forcefully down the side of each tube.  
Step 6: Incubate each tube at 95ºC for 60 min.  
Step 7: Remove from incubation and cool to room temperature in an ice bath for 10 min.  
Step 8: Centrifuge samples at 3000 rpm for 15 min.  
Step 9: Remove supernatant from samples for analysis.  
Step 10: Aliquot 150 l of each standard or sample to duplicate wells in a 96-well plate 
and read absorbance of supernatants at 532 nm. 
